



**TRIENNIUM REPORT: 2022-23 to 2024-25**

**Guidelines and Economists Network  
International**



## Our mission

To facilitate the effective integration of Clinical Practice Guidelines (CPGs), economic and clinical evidence into national decision making and clinical practice in the health sector, especially hospitals and primary care by:

1. Stimulating collaboration between economists, hospitals, and primary care world-wide in translating CPGs, economic and clinical evidence into clinical practice.
2. Achieving participation world-wide by Health Economic Associations, Governments, guideline development agencies, WHO, World Bank, United Nations, OECD, medical and surgical associations, universities, foundations, and national hospital associations.<sup>1</sup>
3. Facilitating health economists to achieve leadership roles in health care organizations to undertake the above activities, applying appropriate technical and clinical governance approaches to localizing CPGs and the evidence into clinical protocols and pathways.
4. Facilitating efficiencies to achieve the above goals by:
  - Identifying key medical and surgical priority areas worldwide for GENI's work program and with regard to funding opportunities to support such work.
  - Encouraging collaboration world-wide in the compilation and proliferation of health economic and clinical evidence and its methodological grading<sup>2</sup>
  - Stimulating the use and development of appraisal of CPGs e.g. Appraisal of Guidelines for Research and Evaluation.
  - Obtaining agreement on cost effectiveness thresholds for CEA, applying the societal perspective where possible.
5. Forging linkages with bodies that set the standards for appropriate treatment under different conditions that may link to contracts or regulatory processes e.g. insurers or national government funding systems.
6. Determining mechanisms whereby CPGs and localized quality instruments such as protocols and pathways can be used by national insurance paying health care providers per individual product and to determine appropriate treatment scenarios related to DRGs, Diagnostic Cost Groups (DCGs) and DBCs (The Netherlands).
7. Identifying and stimulating the financing of GENI's deliberations.

---

<sup>1</sup> UK, England, Scotland, The Netherlands, Australia, New Zealand, Canada, USA, Singapore, Hungary, Poland, Japan, Hong Kong, China, France, Sweden, Switzerland, Germany, Norway, Thailand and Middle East.

<sup>2</sup> Currently mechanisms to grade clinical evidence for CPGs can vary between countries, eg NHMRC (Australia), NICE (UK), SIGN (Scotland) and The Netherlands all use different 'Levels of Evidence' and 'Grades of Recommendations'.

## Our vision

### Achieving participation worldwide

To work towards achieving its goals, GENI is collaborating with Health Economic Associations, Governments, Parliaments, guideline development agencies, WHO, World Bank, United Nations, OECD, medical and surgical associations, universities, foundations, national hospital associations, health service delivery organisations and other health economists and health care professionals.

GENI has established a LinkedIn® Group to facilitate collaboration and share knowledge and ideas.

We look forward to seeing the GENI network grow and sharing insights and approaches to improving evidenced-based care, along with improvements in equity in related national funding and regulation scenarios.



## CONTENTS

Our mission [page 3]

---

Our vision [page 4]

---

### **Section 1 – An overview of GENI**

About us [page 6]

---

Our structure and management [page 6]

---

Our people [page 8]

---

### **Section 2 – Governance**

Chairperson’s report [page 27]

---

CEO’s report [page 30]

---

Our objectives and activities [page 32]

---

Performance awards [page 43]

---

Selected publications [page 45]

---

### **Section 3 – Our Finances**

Simplified operating statement [page 54]

---

### **Section 4 – Our other important information**

Acknowledgements [page 56]

---

Contact us [page 57]

---


## ABOUT US

Guidelines and Economists Network International (GENI) is a not-for-profit international association that aims to drive international mechanisms to integrate Clinical Practice Guidelines (CPGs), clinical and cost effectiveness evidence into national decision making and clinical practice. A key imperative is to forge links with national bodies that set standards, regulation, and funding processes such as governments and insurance bodies.

GENI has a unique focus on achieving both clinical and cost effectiveness in healthcare delivery and equity in related funding worldwide. GENI's vision has been implemented by an international Board of experts from the OECD, United Nations, World Bank, Australia, UK, USA, Canada, China, NZ, Sweden, Africa, and Denmark. The current reach of GENI Board members' work is extensive ranging from impacts at the point of health care delivery and extending through to national Governments and Parliaments.

To achieve GENI's key objectives, we are Identifying key medical and surgical priority areas worldwide, stimulating funding opportunities to support the work and encouraging collaboration worldwide in relevant economic and clinical methodologies.

## Our Structure and Management



Updated as of 14 May 2025



## OUR PEOPLE

### Board members

Name	GENI Position	Professional position(s)
Dr Louis Niessen (USA)	Chair	Professor and Chair of Health Economics, Liverpool School of Tropical Medicine. Honorary professorships and affiliations: Universities of Warwick, Liverpool, and Bologna.
Dr Kathryn Antioch (Australia)	CEO Board member	Principal Management Consultant, Health Economics and Funding Reforms; Adjunct Assistant Professor, Department of Pharmacotherapy, University of Utah USA; Adjunct Senior Lecturer, Department of Epidemiology and Preventive Medicine, Monash University Australia.
Professor Carl Asche (USA)	Deputy Chair	Research Professor, Department of Pharmacology; Executive Director of the Pharmacy Outcomes Research Center, University of Utah College of Pharmacy, Salt Lake City, USA
Dr Michael Borowitz (UK)	Board member	Chief Economist, UK Health Security Agency. Non-executive Director at the National Institute for Health and Care Excellence (NICE), UK
Professor Peter C. Coyte (Canada)	Board member	Professor, Institute of Health Policy, Management and Evaluation, School of Public Health, University of Toronto Canada
Dr Doris Kirigia (Africa)	Board member	Health Economist and Public Health Specialist, WHO
Dr Maureen Lewis (USA)	Board member	CEO, Aceso Global.
Prof Michael Drummond	Past Chair	Professor, Centre for Health Economics, University of York
Dr Ulf Persson (Sweden)	Board member	Senior Advisor, The Swedish Institute for Health Economics, Sweden.
Dr Guy Scott (NZ)	Past Board member	Senior Lecturer in the School of Economics and Finance, Massey University
Dr Meng Qingyue (China)	Board member	Professor in Health Economics, Executive Director, Peking University China Center for Health Development Studies, Director, Key Lab for Health Economics and Policy Studies, China's Ministry of Health
Dr Hindrik Vondeling (Denmark)	Past Board member	Associate Professor in Health Technology Assessment and Health Economics, Centre for Applied Health Services Research and Technology Assessment and Department of Health Economics of the University of Southern Denmark (SDU), Odense, Denmark.
Dr Stuart Peacock (Canada)	Past Board member	Distinguished Scientist, Co-Director, Canadian Centre for Applied Research in Cancer Control, British Columbia Cancer Research Institute
Prof Abdalla Abotaleb (Egypt)	Board member	Project Manager, Health Care Reforms, WHO, Egypt, United Nations; Technical Advisor, Ministry of Health and Population of Egypt; National Organisation for Research and Control of Biologicals (NORCB).

## CEO and Management Team

### Name / title / qualifications



Dr Kathryn Antioch  
Chief Executive Officer

GAICD, PhD (Health Economics)  
MSc, BA (Hons), AFCHSM, CHM

### Biography

Kathryn is CEO, Guidelines and Economists Network International; Principal Management Consultant, Health Economics and Funding Reforms (HEFR); Adjunct Assistant Professor, Department of Pharmacotherapy, University of Utah USA; Adjunct Senior Lecturer, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne; and Member, Department of Foreign Affairs and Trade (DFAT) Specialist Health Service Panel Abt Global.

Kathryn has over 25 years working in senior roles in Government, Private and NFP sectors including Federal and State Governments, Victorian hospitals, a Canadian Royal Commission, GENI and as a Principal Consultant at HEFR. Her leadership roles involve health policy and funding reforms, hospital and government administration, and translational research in medicine and economics. She worked on national pandemic planning. Kathryn advised the Australian Parliament through participating in 18 Senate Inquiries, including COVID-19. She participated in Senate Committee Public Hearing Inquiries on Council of Australian Government health reforms and Fetal Alcohol Spectrum Disorder.

She held Ministerial appointments to two Principal Committees of the National Health and Medical Research Council (NHMRC) concerning public health and clinical guideline regulation for 6 years. She was Editorial Board member and Associate Editor, Cost Effectiveness and Resource Allocation Journal.

As CEO GENI, Kathryn forges links with national bodies that set standards, regulation, and funding processes. This aims to achieve cost effectiveness in healthcare delivery, equity in related funding and Value Based Health Care (VBHC). She leads translational research concerning the COVID-19 pandemic; H5N1; HKU5; CPG regulation in Australia, UK, Canada, USA, The Netherlands, Sweden, Norway and Denmark; Digital Health Interventions and AI; VBHC; Value Based Reimbursement, and Non-communicable disease management during the COVID-19 pandemic in Western Pacific and SE Asian regions. Earlier priorities included vaccinations, diabetes, cancer, and cystic fibrosis. Her recent work at GENI is published in four international journals. Her earlier research on Activity Based Funding risk adjustment reforms is published in 3 editions of the European Journal of Health Economics. As Principal Management Consultant, HEFR, she has consulted for Frontier Economics; two Victorian Government Departments; Commonwealth Department of Health and Ageing, DFAT, Independent Hospital Pricing Authority (now IHACPA), NHMRC, PWC, WHO, World Bank, Western Health, ANU, Siemens Health Care, Health Direct Australia, a Centre of Excellence of Health, AHHA, and Water Services Association of Australia.



Peter Landers

Director, Finance and Governance

B Bus (University of Southern  
Queensland) MBA (RMIT  
University) FCA FCPA CFP  
GAICD

Peter Landers is a Financial Adviser with a wealth of experience in Chartered Accounting and Financial Advisory, along with the practical backing of experience in commerce and high-level enterprise management. His professional life, spanning 37 years, has incorporated finance and management roles within both Commerce and Chartered Accounting, including Chief Executive Officer of the Melbourne Division of an international accounting firm. As the founder of Salt Financial Group, his personal focus is as an adviser to the owners and operators of small and medium enterprises.

Peter has held various Directorships within the Private Sector and several Community Organisations, providing consultancy services for medical specialists, surgeons, and the NSW Cancer Council. He has held the role of Secretary of the Australian Society of Aesthetic Plastic Surgery. He was Director of the Umbrella Superannuation Fund, now part of the Crowe Horwath Group, administering \$100m in members' funds. This organisation is the largest provider of practical accounting, audit, tax, business and financial advice to individuals and businesses from a network of over 80 offices throughout Australia and New Zealand.



A/Prof Priscilla Robinson PhD  
(Epidemiology)  
Executive Director, International  
Health, and Epidemiology

PhD Epidemiology (Melbourne  
University), MPH (Monash  
University), MHS (Public Health  
Practice) (La Trobe University)

A/Prof Robinson was appointed Executive Director, International Health and Epidemiology, GENI in November 2023. This followed her work as a Director for GENI since 2016 when she worked on 'The management of chronic diseases during the COVID-19 Pandemic in the WHO Western Pacific and SE Asian regions', the 'Africa COVID-19 vaccine project'; and 'Cost Effectiveness Analysis of Child Vaccinations in Africa: International Lessons for CPGs in Developing Countries'.

In 2021 she was awarded the GENI Award for Outstanding Contribution, and in 2022 the Australasian Public Health Association President's Award for her outstanding contribution to the betterment of public health in Australia.

She has a PhD in Epidemiology and an international reputation in Epidemiology and Public Health, with considerable experience working in Australia, England, and several countries in Asia and Africa. Her experience in communicable disease surveillance and control and public health emergency management and recovery, especially in remote areas of Australia and developing countries spans several decades.

Her current work concerns the standardisation of international public health core competencies and, when capacity allows, the role of the arts in public health. She is co-chair of the World Federation of Public Health Associations sub-group on Professional Education and Training. She is a member of the Steering Committee of the *WHO Roadmap to Secure the Public Health and Emergency Workforce* and is co-chair of the Roadmap Technical Advisory Group for Competency Based Education.

Before relocating to the UK in late 2022, she was a long-standing editor for the *Australian and New Zealand Journal of Public Health*, for several years for the *Australian Epidemiologist*, and was on the Editorial Board of the *Journal of Peace and Security* and currently edits for *Public Health Reviews*. She was also Board member and deputy chair for the South Gippsland Health Service, Victoria and for CONCERN Australia, a faith-based NGO.



Dr Rick Marshall

Director, Value Based Health Care  
and Performance Epidemiology

PhD, Epidemiology (ANU),  
Graduate Management Certificate  
(University of NSW), Health  
Economics Postgrad Certificate  
(University of Sydney), Diploma  
Applied Psychology, Clinical  
(University of Tasmania),

Dr Rick Marshall OAM is an international consultant on healthcare Case-Based activity measurement, pricing, and performance management. He is a former clinician, healthcare service manager and system developer. He has held Professorial appointments with the Faculty of Health Sciences at the University of Sydney and the Institute of Global Health Innovation at Imperial College London. He specializes in healthcare system performance analysis, Patient Based Funding reform and Management Information Development for healthcare.

He has extensive experience in senior executive and advisory roles in the Australian Federal, Victorian, NSW and ACT governments, the Independent Hospital Pricing Authority and governments in Ireland, England, and Hong Kong.

Dr Marshall led the teams that initially established the Australian DRG system and the Activity Based Funding (ABF) mechanisms for Australia's Independent Hospital Pricing Authority. He established the role of Director of Pricing for the NHS in England and has held the appointment of Chief Expert on Casemix and Activity-Based Funding and Payment in China's National Health Development Research Centre.

Rick's recent activities have included providing advice on and support in value-based healthcare innovation and performance improvement programs to Governments, payer organisations and individual providers in Africa, Asia/Pacific, Europe, Middle East, and North America. These interests include various project roles with WHO, World Bank and other international development organisations.



Fiona Sherwin  
Executive Director, International  
Health Policy and Sustainability

B Physio (Hons) (Melbourne  
University) G Cert Public Health  
(Flinders University) MHA (La  
Trobe University) MBA  
(Melbourne University) FCHSM

Fiona was promoted to Executive Director, International Health Policy and Sustainability, GENI during August 2024. This followed her work as Director of Allied and Community Health at GENI since May 2017. She had worked as a researcher for GENI since 2014. Fiona has contributed to systematic reviews on the cost effectiveness evidence related to type 2 diabetes mellitus, cystic fibrosis, prostate cancer, and maternal and child vaccinations. More recently she researched the potential impact of public health infrastructure on COVID-19 vaccination campaigns in different jurisdictions.

As an experienced physiotherapist and health service manager, Fiona is passionate about using graded evidence to inform decision making at all levels. She is committed to addressing social inequity and promoting health system efficiency. Since March 2025, Fiona has worked as the National Manager, Strategy and Growth, Bolton Clarke and is also Project Fellow, Sustainable Health at University of Melbourne. This followed her work as Senior Transformation Partner at Monash Health, Melbourne from 2022 to 2025. As the Senior Project Officer in the Office of the Chief Executive at Monash Health she assisted establishing interventions as part of the COVID-19 response from 2020 to 2022. Previously, Fiona oversaw the Physiotherapy Department at Dandenong and Casey Hospitals, where she was responsible for leading weekend and outpatient services reviews. Fiona has held various project and leadership roles at Knox Private Hospital (Healthscope), Alfred Health and the Australasian College of Health Service Management.



Meg Bumpstead  
Director, Perioperative and Critical Care  
Nursing and Otology

MBA (Deakin University), Aural  
Care, Clear Ears (University of  
Melbourne), Post Grad Dip Advanced  
Clinical Nursing – Intensive Care  
(University of Melbourne), Bachelor  
Applied Science Nursing (La Trobe  
University)

Meg Bumpstead was promoted to Director, Perioperative and Critical Care Nursing and Otology, GENI during 2024 following her work as Senior Project Manager, GENI. Meg is a Health Management Consultant, Founding Director Clear Ears Pty Ltd and Critical Care Registered Nurse. She has a long-standing passion for improving quality and access to health care. Meg has over thirty years experience in the health sector with roles in hospital management, freelance management consulting, community health board director, health service start-up, critical care clinical practice and in education. Meg also participates on international aid missions.

Meg currently works as a consultant on Clinical Panels providing health management advisory services to both Government and the Private Sector, whilst also managing Clear Ears as a co-founder – having recently expanded the Clear Ears Learning training to Europe. Meg continues to also practice part time Critical Care Nursing, in both Post-Anaesthesia Care Unit (PACU) and Anaesthesia in a busy fifteen theatre complex providing surgical services across all surgical specialties excluding trauma services.



Billie Atanasova  
Director, International Funding  
and Research

BHSc (Hons) (La Trobe University),  
MPH (Melbourne University),  
AFCHSM, CHE

Billie Atanasova was appointed Director, International Funding and Research, GENI in June 2016. Since November 2024 she has held the role of Head of Business Optimisation at Prime Super. From 2019 to 2024 she was the National Sales Manager, Corporate Super at Prime Super. With over 22 years' experience in the health sector, Billie is an experienced health executive, project manager, researcher, evaluator, and mentor who has worked across various public, private, and corporate settings.

Billie has held senior roles at the Australasian College of Health Service Management (ACHSM), including Executive Officer (Victoria) and Manager, Policy, Advocacy and Management Residency Program. During her tenure at the ACHSM Billie fostered productive collaboration with GENI through the ACHSM's residency program and her effective stakeholder engagement via facilitating a televised policy debate on key 2014-15 Victorian Health Budget policy initiatives, involving the Victorian Government, CEO, GENI and several hospital CEOs. Billie has contributed to large-scale public health projects aimed at investigating environmental, genetic, and behavioural contributing factors of disease prevalence, and researching alternative treatments to various cancers.

She has extensive experience in identifying opportunities and preparing health services research grant funding applications. She increased the number of grant submissions by the ACHSM by 3-fold in a 12-month period and prepared National Health and Medical Research Council (NHMRC) grants. Billie's experience in evidence-based research, evaluation and funding is a great value add to the work of GENI.



Angeline Kuek

Executive Director, International Health Reforms

BBSocSci (University of Melbourne), BSc (Hons) (University of Melbourne), Master of Public Health (University of Adelaide), Master of Health Administration (Latrobe University).

Angeline was promoted to Executive Director, International Health Reforms in 2023 following her work as a Director. She previously worked as Senior Project Manager, GENI during 2018 on studies pertaining to 'Cost Effectiveness Analysis of Child Vaccinations in Africa: International Lessons for Clinical Practice Guidelines in Developing Countries' and 'Cost Effectiveness of Prostate Cancer screening and diagnostic strategies: International Lessons for Clinical Practice Guidelines.'

From 2017 she worked on the project concerning 'Non-Communicable Disease (NCD) Crisis in the Pacific Multi-sector Collaboration, Regulation and Cost-Effective Innovation'. Angeline is a Principal Policy Adviser in the Victorian Department of Health. She previously held the roles in the disability sector and was Senior Consultant at KPMG's Health, Ageing and Human Services team. She has extensive experience in project management and has worked across a variety of projects concerning digital health, mental health, safety and quality, service re-design and service and program evaluation. She has research experience concerning eating disorders and mental health at the Singapore General Hospital and the Statewide Eating Disorder Service in South Australia.

Angeline is passionate about ensuring that people get access to the right care at the right time and has a strong interest in mental health, public health, healthcare delivery, health equity, health economics, population health and chronic disease.



Rhonda Kerr

Executive Director, Economics, Health Services and Planning

B.A (Economics) ANU; GAICD 2009; Doctor of Philosophy (Ph.D.) Curtin University.

Professionally, Rhonda Kerr is Senior Clinical Services Planner, Hames Sharley; Director, Rhonda Kerr and Associates Health Planning and Director, Recovery Inn Pty Ltd developing Medi hotels in Western Australia. Rhonda is closely involved in corporate governance chairing a charitable foundation for children and youth in Western Australia, and a member of a number of Boards and committees.

She has extensive experience in the use of clinical guidelines in a wide variety of health settings for hospital and health service planning throughout Australia, New Zealand, Malaysia, Fiji, and India. As a contributor to the UIA-Public Health Group she contributed to international collaborations on evidence-based change for health service delivery. She has participated in Federal Parliament Senate Inquires on health reforms in Australia and was referenced in the interim reports of both the Productivity Commission Review of private and public hospitals and the National Health and Hospitals Reform Commission.



John Pilla

Executive Director, Health Funding Policy, and Program Evaluation

Bachelor of Science (Hons), (University of Adelaide), Graduate Diploma in Business Administration, (University of South Australia) Member and Committee Chair, Australasian Evaluation Society.

John has worked in the private and public health care sectors for over 30 years in a range of roles including Director, KPMG's national healthcare practice and prior to this, he held executive roles in federal and state governments. John has been involved for several years in national hospital funding policy development and has extensive health program evaluation experience. John operates his own consultancy practice and is an evaluation advisor for a range of organisations including an Indigenous owned organisation. He is a recipient of a national award for best practice in evaluation and is the Chair of the South Australian Australasian Evaluation Society Coordinating Committee.

John's evaluation experience covers a wide range of policies, methodologies, and functions. John has evaluated national reforms in aged care, primary health care and Aboriginal and Torres Strait Islander health care that led to fundamental reform. His involvement in the evaluation of the coordinated care trials led to reforms of general practice. John has been at the forefront of hospital funding policy development for several years. More recently, he worked with the Department and Prime Minister and Cabinet on the development of a national hospital funding system and with the Independent Hospitals Pricing Authority on various improvements to the national funding system.



Helen Sinnott  
Director, Chronic Disease  
Management and Clinical  
Guidelines

Helen is the Lead Healthcare Executive at Oracle Health. Prior to that she was Director, Nursing and Midwifery at Western Health in August 2021. She also has extensive experience as the Director of Nursing and Midwifery Informatics and Chief Nursing and Midwifery Informatics Officer at Western Health. She is the former Executive Officer of the Australian Disease Management Association (ADMA), a clearing house of expertise in disease management. It provides a forum and advocacy for disease management services to promote programs, which improve outcomes and quality of life and reduce acute health care utilisation and costs in patients with chronic conditions.

Helen has been employed in health care in the UK, USA, and Australia for over 20 years and brings a wealth of experience in healthcare and project management having been instrumental in the development of the chronic disease management services at Western Health including model development and evaluation. She also has experience with health reform while Change Manager with the National Health Workforce Taskforce. In this role she was involved in the development of a national program to test and demonstrate major shifts in workforce utilisation and deployment across all sectors of aged care. Helen has also been actively involved in the development of the Integrated Chronic Disease Management Online Clearinghouse. At Western Health in Melbourne, Helen was involved in the process of integrating clinical practice guidelines and clinical and economic evidence into practice, including researching and grading evidence, through participation in the Clinical Pathways Working Group.

Helen was promoted to Director, Chronic Disease Management and Clinical Guidelines, GENI following her work as Senior Project Manager, GENI.



Dr. Binaya Chalise

Director, Health and International  
Development

MPH, (La Trobe University,  
Australia), BPH (Nepal Institute of  
Health Sciences) Proficiency  
Certificate in General Medicine  
(Nepal Institute of Health  
Sciences) PhD (Hiroshima  
University Japan)

Binaya Chalise is a Research Fellow at the Hiroshima University. He also worked at the Tribhuvan University as an Adjunct Lecturer. Dr Chalise has prior experience working as a Research Associate at the Nepal Health Research Council and is a Scientific Committee member of the National Summit of Health and Population Scientists in Nepal. At the Nepal Health Research Council, he undertook extensive collaboration with researchers on conducting systematic reviews in the Council's priority areas to facilitate the translation of clinical evidence into policy and clinical practice in Nepal. He also worked with the Ministry of Health to develop National Health Account of Nepal.

With broad experience, leading the development and implementation of public health programs, Binaya Chalise has a decade-long career in public health research and clinical practise. His experience in clinical medicine and public health has involved extensive travel across Nepal and to Australia, involving experience of coordinating public health research and international operations across varied and multi-cultures in both developed and developing nations. He has undertaken extensive research on health care policies and procedures to analyse clinical and cost effectiveness evidence and to recommend appropriate remedial action. Whilst working at the Nepal Health Sector Support Program, he travelled throughout Nepal to locations severely impacted by the 2015 earthquake, to analyse health delivery practices and to implement recovery strategies based on the disaster management, economic and clinical evidence assessed from a stock take assessment.



Dr. Yen Cheng Henry Pan  
Director, Medicine, Epidemiology  
and Clinical Guidelines

M.B.B.S (Hons), Bachelor of  
Medicine/Bachelor of Surgery  
(Honours), Faculty of Medicine,  
Nursing and Health Sciences,  
Monash University, Victoria,  
Australia BMedSc (Hons), Bachelor  
of Medical Science (Honours),  
Central Clinical School, Alfred  
Health, Faculty of Medicine,  
Nursing and Health Sciences,  
Monash University, Victoria,  
Australia



Dr Nigel Anderson  
Executive Director Oncology and  
Clinical Guidelines

Doctor of Philosophy (PhD)  
Monash University; Ba App. Sci  
(Medical Radiations) RMIT; Ba App  
Sci (Human Biology) RMIT

Henry is a Junior Medical Officer at Melbourne Health at the Royal Melbourne Hospital, having completed his MBBS (Hons) in 2019 at Monash Medical School. He has undertaken clinical placements in all areas of medicine and surgery throughout his medical degree at hospital networks around Victoria including Monash Health, Alfred Health, Peninsula Health and Bendigo Health.

Henry was promoted to Director, Medicine, Epidemiology and Clinical Guidelines in December of 2019, following his involvement in the projects 'Cost Effectiveness of Prostate Cancer Screening and Diagnostic Strategies: International Lessons for Clinical Practice Guidelines' and 'Cost Effectiveness Analysis of Child Vaccinations in Africa: International Lessons for Clinical Practice Guidelines in Developing Countries' in his previous role as Senior Project Manager. This follows his contributions as a Researcher and Project Manager for GENI since 2015, contributing to two systematic review studies concerning 'Personalised Medicine, Genetics and Economics: Cystic Fibrosis Lessons for Quality, Guidelines and Policy Reforms' and 'Cost Effectiveness Evidence for interventions for Type 2 Diabetes: International Lessons for Clinical Guidelines'.

Henry intermitted his medical degree in 2018 to undertake a Bachelor of Medical Science (Honours) in Urology at Alfred Health, supervised by Professor Grummet, focussing on prostate cancer diagnostics with the latest in radioactive Gallium-68 tracers and cutting-edge PET/CT and PET/MRI diagnostic imaging. He has completed a research project in Urology at Monash Health, entitled "Can We Trust Sonographic Urinary Tract Stone Size?", and has a keen interest in pursuing urology as his chosen specialty following graduation.

Nigel was appointed Director, Radiation Oncology and Clinical Guidelines, GENI during January 2017 and was subsequently promoted to an Executive Director role. During December 2021, he was promoted to Radiation Therapy Manager at Austin Health. He previously held the role of Principal Research Radiation Therapist, Peter MacCallum Cancer Centre since November 2015. This work required extensive multidisciplinary collaboration within the Peter MacCallum Cancer Centre and with several external partners, to enable innovative radiation oncology practice in a highly technical and collaborative profession.

Nigel has ten years prior experience working as a clinical radiation therapist at the Olivia Newton John Cancer Wellness and Research Centre in Melbourne where he facilitated the clinical implementation of a new radiotherapy treatment planning system and a stereotactic radiotherapy program, in accordance with Clinical Practice Guidelines.



Denny John  
Director, Health Economics and  
Evidence Synthesis

Bachelor of Physiotherapy  
(Mangalore University, India),  
MBA-Hospital Management  
(IHMR, Jaipur), Master of Public  
Health (University of Auckland).

Denny John is an Adjunct Professor at the Prasanna School of Public Health and also the University of Adelaide in Australia. Since 2020 he has held the role of Chair of the Campbell and Cochrane Economics Group (CCEMG) and is an Associate Editor, Economics at Cochrane EPOC.

Denny John is Evidence Synthesis Specialist, Campbell Collaboration, and based in New Delhi since December 2016. He has over 13 years' experience across health services management, project manager, researcher, evaluator, and academic across public, private, and corporate settings.

He has experience working with development organisations, insurance companies, and healthcare consulting, conducting economic evaluation, systematic reviews, and disease forecasting studies. His experience spans working in India and Nepal, and supporting community health financing projects in Bangladesh, Tanzania, Nigeria, and Ghana. He has been the Principal Investigator/Co-Investigator for over 15 research studies conducted across various states in India and has been awarded several research and project grants from national and international bodies.



Dr Sasan Adibi  
Director Digital Health Interventions and  
Artificial Intelligence

PhD Communications and Information  
Systems (University of Waterloo, Canada),  
MSc (University of Windsor, Canada), MSc  
(Brunel University, UK), Senior Member, IEEE  
(SMIEEE)

Dr. Sasan Adibi was appointed to the role of Director, Digital Health Interventions and Artificial Intelligence at the Guidelines and Economists Network International (GENI) during February 2025. He is a distinguished leader in digital health innovation with over two decades of experience spanning academia, industry, and government sectors.

GENI's research agenda places a very high priority on the use of digital technologies and AI in healthcare and clinical guidelines. Dr Adibi contributes to GENI's work in this area and participates in the Digital Health Interventions Sub-committee of GENI's Clinical Practice Guidelines Innovation Steering Committee.

Dr. Sasan Adibi also holds the role of CEO at Founder Research Vitality where he drives innovation in digital health. After completing his PhD in Communication and Information Systems at the University of Waterloo, for which he received the Institute of Electrical and Electronics Engineers (IEEE) Society's best thesis award, he established himself as a pioneering researcher and practitioner in health informatics.

His contributions to the field include over 100 academic publications, six edited books focusing on Mobile Health and COVID-19, and five US patents in Health Informatics. Dr. Adibi's industry experience encompasses leadership roles at prominent technology companies including BlackBerry Corp., Huawei Technologies, and Hyundai KIA America Technical Centre, where he led groundbreaking projects in digital health.



Dr David Warncken  
Director, Medical and Clinical Guidelines  
Research

MD (Flinders University), Bachelor of  
Medical Science (Flinders University),  
Graduate Diploma Addiction and Mental  
Health (Adelaide University).

Dr Warncken was promoted to the role of Director, Medical and Clinical Guidelines Research, at GENI during May 2024. He is a member of the Clinical Practice Guidelines (CPG) Development Sub-committee of GENI's CPG Innovations Steering Committee. During 2024, he participated in research concerning CPG development practices in Australia, involving the use of economic, clinical, and epidemiological evidence, digital health, governance processes and international best practice. He also investigates the role of standards in Australia's Quality Commissions and identifies the implications for Value Based Health Care. He plans to undertake research relating to Australian and international guidelines in Nephrology.

David's involvement with GENI commenced as a researcher with the management team on 'Cost Effectiveness of Prostate Cancer screening and diagnostic strategies: International Lessons for Clinical Practice Guidelines' (2018). He then gained experience in the study concerning 'Cost Effectiveness Analysis of Child Vaccinations in Africa: International Lessons for Clinical Practice Guidelines in Developing Countries'. He was promoted to senior project manager during December 2019.

David is completing Advanced Training in General Medicine with the Royal College of Physicians (RACP) and currently holds employment as a senior medical registrar at the Royal Melbourne Hospital, Victoria, Australia. Upon completion, he will be qualified as an Acute and General Care Physician. He trained in Adelaide, South Australia, and previously worked with both Southern and Central Local Adelaide Health Networks.



Lauren Richardson  
Director, Evidence Based Medicine  
and Health Policy

Bachelor of Health Science (BHSc)  
(Victoria University), Bachelor of  
Medical Science  
(BMedSc) (Hons) (University of New  
South Wales), Dual Master's  
degree, Public Health and Global  
Health (University of New South  
Wales).

Lauren was promoted to Director, Evidence Based Medicine and Health Policy during November 2023, following her work as Senior Project Manager, GENI since 2018 on studies pertaining to 'Cost Effectiveness Analysis of Child Vaccinations in Africa: International Lessons for Clinical Practice Guidelines in Developing Countries' and 'Cost Effectiveness of Prostate Cancer Screening and Diagnostic Strategies: International Lessons for Clinical Practice Guidelines.' As Researcher, GENI during 2016-17, Lauren worked with members of the GENI management team on projects concerning Clinical Practice Guidelines for Cystic Fibrosis, and starvation in Africa. Lauren was awarded the GENI Award for Outstanding Contribution in 2019 in recognition of her achievements.

Recognised as one of the Australian Financial Review's Top 100 Future Leaders, Lauren has extensive experience in public health policy and has substantial experience in driving policy and reform in dynamic, challenging environments. She recently worked as a Project Manager at Victorian Department of Premier and Cabinet. She currently works as Executive Officer, Australian Health Promotion Association. Appointed by the Strategic Initiatives Committee of a major Primary Healthcare Network, she provided vital guidance on novel care models and regional healthcare reform. Her comprehensive paper on primary healthcare challenges and opportunities yielded six accepted recommendations to the Board, including a visionary merger of care models for a 2024 cardiac pilot.

In 2022, Lauren supported the Grattan Institute's Health and Aged Care Program. Her research and analysis of benchmark trends in disease prevention and control contributed to solutions for some of Australia's most pressing health policy issues. Prior to this, Lauren played a pivotal role in leading and coordinating essential aspects of the Victorian Government's response to COVID-19 from 2021 to 2022. As Chief Executive Officer, Community Health Advancement and Student Engagement (CEO, CHASE), Lauren developed and led the 2023 strategic plan, championing a holistic approach to integrate health promotion into the organisation's strategy, fostering excellence and continuous improvement.



Denise Seidel (Pottumati)  
Director, Legal and Governance Research

Master of Business Law (MBL) (Southern Cross University), Bachelor of Accounting (BAcc) (University of South Australia), Diploma of Commerce (SIBT/Macquarie University), Diploma of Business Administration (Williams Business College).

Denise works as Research Development Manager at the Faculty of Science, University of Technology Sydney (UTS). Her work involves the development of research strategy, research management and pre-award research engagement activities.

At the Guidelines and Economists Network International, she was promoted to Director, Legal and Governance Research, GENI in October 2022. She previously held the positions of Senior Project Manager, 2020-22, Project Manager, 2019-2020 and Researcher GENI, 2017-2018.

Denise was awarded the 2020 GENI Award for Outstanding Contribution. At GENI, Denise's contributions have involved research into the Australian Charitable Accounting Standards relating to Annual Reports and the identification of research funding opportunities for GENI. This includes funding opportunities for research concerning COVID-19 in Australia and internationally, development of a summary of Australian Government specifications for categories of research. She also prepared a briefing for GENI's Chief Executive Officer on the Export Market Development Grants scheme (EMDG) and the Medical Research Future Fund (MRFF).

Previously Denise was the Research Manager for the Faculty of Transdisciplinary Innovation, Engagement Manager (Acting) and Research Engagement Associate for the central Research Innovation Office at UTS.

Denise has prior experience as a project/centre administrator at the Centre for Health Systems and Safety Research, Australian Institute of Health Innovation, Macquarie University, NSW. Denise coordinated activities for the Centre including financial management of projects and grants, human resources, support of funding proposal applications and general office activities such as marketing, communications, and website maintenance.

## Project Managers and Researchers

Name	GENI / professional position	Qualifications
Nigel Pratt	Senior Project Manager, GENI Clinical Research Coordinator, Infectious Diseases Unit, Burnet Institute, Alfred Hospital	Degrees, nursing (LaTrobe University) Masters, public health (LaTrobe University) International Health Economics Course (LaTrobe University)
Dr Symret Singh	Senior Project Manager, GENI Medical Doctor, Royal North Shore Hospital, Sydney Clinical Associate Lecturer. University of Sydney	Bachelor of Commerce (University of Sydney) Doctor of Medicine (University of Wollongong) Master of Public Health candidate (University of Sydney)
Kaylene Fiddes Ryan	Senior Project Manager, GENI Health Services Management Consultant, Beness	Advisory Committee, Australian Disease Management Association (ADMA)
Dr Sahar Daghigh Yazd	Senior Project Manager, GENI	PhD, Applied Health Economics (University of Adelaide, Australia); Master's degree, Applied Economics; Bachelor's degree, Statistics
Gideon Meyerowitz- Katz	Project Manager, GENI	BSc (University of Sydney), Master of Public Health (University of Sydney)
Jhai Madden	Project Manager, GENI	Bachelor of Science (Melbourne University), Master of Public Health (MPH) (Melbourne University), Master of Health Administration (MHA) (La Trobe University)
Arya Pawar	Researcher, GENI	Bachelor of Biomedical Engineering (RMIT University) Certificate of specialisation – Health Care Economics (Harvard Business School)

## Medical Advisory Committee

Name	Professional position	Qualifications
	<p>Professor of Medicine and Head of the Department of Medicine, Melbourne Medical School, The University of Melbourne Director of Research and James Stewart Professor of Medicine, Royal Melbourne Hospital (RMH) and University of Melbourne</p>	<p>BMedSc (Hons), MBBS Monash, MD Monash, FRACP</p>
	<p>Public Health Physician Clinical Professor of Public Health, Australian National University (ANU) School of Medicine and Psychology. Former Senior Specialist Chronic Disease, Canberra Health Services (2020-2022).</p>	<p>BMBS, MA, MPH, PhD, FAFPHM, GAICD</p>
	<p>Director of Rehabilitation Services, RMH, Director Australian Rehab. Research Centre, Clinical Professor Dept. of Medicine, University of Melbourne, and Nossal Institute of Global Health, and Monash University Vice Chair, ISPRM Board member, RMSANZ Inaugural Academic Fellow to board of AFRM, RACP</p>	<p>MBBS FAFRM MD AMC</p>



Professor Danny Liew

Executive Dean, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland.

MBBS (Hons), BMedSc(Hons), FRACP, PhD, Cert Health Econ



Professor Jeremy Millar

Director of Research, Alfred Health Radiation Oncology  
Head of Brachytherapy, Alfred Health  
Deputy Chairman, Cancer Council Australia  
Chair, Cancer Council of Victoria

BMedSc, MBChB, FRANZCR, FACHPM



Professor Paul Myles

Professor and Director, Department of Anaesthesia and Perioperative Medicine, Alfred Hospital

Chair of the Monash University Department of Anaesthesia and Perioperative Medicine, Melbourne, Australia

MBBS, MPH, MD, DSc, FCAI, FANZCA, FRCA, FAHMS



Dr Ifelayo Ojo

Pediatric resident, University of Minnesota, USA

Bachelor of Medicine, Bachelor of Surgery (MBBS), Master of Public Health (MPH)



Professor Max A.  
Schwarz, AM

Former Head of the  
Medical Oncology Unit,  
Alfred Hospital,  
Melbourne Australia

MBBS (Hons) FRACP FACP FChPM



Professor Duncan Topliss

Director of the  
Department of  
Endocrinology and  
Diabetes, Alfred  
Hospital, Melbourne  
Australia

MB BS Hons, MD, FRACP, FACE



Professor John Wilson  
AM

Consultant Physician and  
Policy Adviser.

Former Head, Cystic  
Fibrosis Service, Alfred  
Hospital, Melbourne  
Allergy, Immunology and  
Respiratory Medicine  
(AIRMed) Department  
(1992- 2022), Monash  
University. Melbourne  
Past President Royal  
Australasian College of  
Physicians (2020-2022).

B.Sc (Hons), MBBS Melbourne, PhD Melbourne,  
FRACP

## CHAIRPERSON'S REPORT

**Professor Louis Niessen**



The Guidelines and Economists Network International (GENI) was established at the 2006 European Health Economists Conference, Hungary to enable health economists world-wide to work with peak international bodies, health services and governments in this area. Linkages to both evidence-based medicine, service delivery and related government regulatory and funding systems are central. GENI has 12 Board members, and has included members from the United Nations, UK, New Zealand, Australia, USA, World Bank, OECD, Canada, China, Denmark, The Netherlands, Africa, and Sweden.

GENI Conference Satellite Sessions and/or Board meetings have been held in Hungary (Budapest), Denmark, Italy (Milan), China (Beijing), Canada (Toronto), USA (Boston), Australia (Sydney) and Indonesia (Bali) since 2006. Earlier Organised sessions on guideline and economic issues were also conducted by key participants in the United Kingdom (York and London) and Spain (Barcelona) prior to GENI's formation. GENI involves over 1,118 affiliate members, along with a management team including a CEO, Medical Advisory Committee, Executive Directors, Directors, senior managers, and researchers.

Importantly, issues concerning the vision for GENI were published in the 'Cost Effectiveness and Resource Allocation' journal (1) in 2017 by four GENI board members including the CEO. There we mentioned that the use of the Consolidated Health Economics Evaluation Reporting Standards (CHEERS) statements are key elements of the work of the GENI on assessing the economic literature. Important updates to CHEERS have recently been developed, which can further guide GENI's work in health economics. That work has been published in 'Value Health' and is a Report of the ISPOR CHEERS Good Practices Task Force (2).

Professor Carl Asche, GENI's Deputy Board Chairman is leading the ISPOR CHEERS Digital Health Interventions Task Force, in collaboration with GENI's Digital Health Interventions (DHI) and Artificial Intelligence (AI) Sub-committee of the CPG Innovations Steering Committee. This is assisting with assessing the economic literature concerned with DHI and AI.

Through our CEO, Management Team and international affiliates, we facilitate communication and collaboration with the National Health and Medical Research Council (NHMRC), Australian Parliament, Cochrane Collaboration, Guidelines International Network, International Health Economics Association, National Guidelines Clearing House AHRQ, National Institute for Clinical Excellence, WHO, Centre for Disease Control, Australian and international governments, universities, medical and surgical associations.

GENI's CEO and executive staff published leading edge international journal articles during 2023, 2024 and 2025. These demonstrate GENI's global leadership in health economics and clinical guidelines in areas such as:

- The economics of the COVID-19 pandemic: economic evaluation of government mitigation and suppression policies, health system innovations, and models of care (3).
- A multi-criteria decision analysis (MCDA) framework that prioritizes economic policy to enhance value-based health care during the COVID-19 pandemic (4)

- The management of chronic diseases during the SARS-Cov2 pandemic in WHO Western Pacific and Southeast Asian Regions (5)

Importantly, the publications concerning the economics of the pandemic and MCDA methods spearhead new methodologies to address complex policy and economic challenges at the societal level, involving the integration of welfare economics concepts during international public health emergencies.

This Triennium Report demonstrates that GENI has provided an effective umbrella for like-minded researchers in achieving the aims implied by GENI's mission. We believe that GENI has the capability to achieve even more as appropriate funding becomes available.

The multi-disciplinary nature of GENI teams has facilitated success in our endeavours. We effectively involve experts in epidemiology, health policy and financing, economics, physicians, law, clinicians, allied health, digital health interventions and artificial intelligence.

(1) Antioch KM, Drummond M and Niessen L, Vondeling, H (2017) 'International Lessons in New Methods for Grading and Integrating Cost Effectiveness Evidence into Clinical Practice Guidelines' *Cost Effectiveness and Resource Allocation Journal*. 15:1 pages 1-15 <https://resource-allocation.biomedcentral.com/articles/10.1186/s12962-017-0063-x>

(2) Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) (2022) Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force. *Value Health*. 2022 Jan;25(1):10-31. doi: 10.1016/j.jval.2021.10.008. <https://www.sciencedirect.com/science/article/pii/S1098301521017952>

(3) Antioch, KM (2023) The economics of the COVID-19 pandemic: economic evaluation of government mitigation and suppression policies, health system innovations, and models of care. *J Public Health (Berl.)* <https://doi.org/10.1007/s10389-023-01919-z>

(4) Antioch KM, Kuek A, Pilla J, Marshall R. (2024) A multi-criteria decision analysis framework that prioritizes economic policy to enhance value-based health care during the COVID-19 pandemic. *Discover Health Systems* 3, 12 <https://doi.org/10.1007/s44250-024-00070-0>

(5) Kuek, A, Antioch KM, Robinson, P (2025) The management of chronic diseases during the SARS-Cov2 pandemic in WHO Western Pacific and Southeast Asian Regions *J Public Health* <https://doi.org/10.1007/s10389-025-02515-z>

**Professor Michael Drummond retires as GENI Board Chairman**

Professor Michael Drummond retired as GENI Chairman of the Board on 18 August 2023 following 17 years of outstanding contribution in that leadership role. Professor Drummond joined the GENI Board in July 2006 at the formation of GENI at the European Health Economists Conference and became Chairman. Michael is also the former Director of the Centre for Health Economics, York University United Kingdom.

Departing Chairman said, “It has been a great opportunity for me to serve as GENI Chairman over the past 17 years including Board meetings and Organised Sessions at the International Health Economists Association (IHEA) World Congresses in Hungary, Denmark, Italy, China, Canada, USA, Australia, England, and Spain”.

Michael Drummond is Professor Emeritus and former Director of the Centre for Health Economics at the University of York in the United Kingdom. His main field of interest is in the economic evaluation of health care treatments and programmes. He has undertaken evaluations in a wide range of medical fields including care of the elderly, neonatal intensive care, immunization programmes, services for people with AIDS, eye health care and pharmaceuticals. He is the author of two major textbooks and more than 700 scientific papers. He has been President of the International Society of Technology Assessment in Health Care, and the International Society for Pharmacoeconomics and Outcomes Research.

In October 2010 he was made a member of the National Academy of Medicine in the USA. He has advised several governments on the assessment of health technologies and chaired one of the Guideline Review Panels for the National Institute for Health and Care Excellence (NICE) in the UK. He is currently Co-Editor-in-Chief of Value in Health and has been awarded 3 honorary doctorates, from City University (London), Erasmus University (Rotterdam) and the University of Lisbon. He was a member of the Steering Group for the 2020-22 NICE Methods Review.

Professor Drummond was succeeded as GENI Chairman by the Deputy Chairman, Professor Louis Niessen. Louis is Professor International Health and Chair of Health Economics, Liverpool School of Tropical Medicine, United Kingdom and Adjunct Professor, John Hopkins Bloomberg School of Public Health USA.

Professor Niessen said “I am honoured to have been asked by my peers to take on this leadership role at GENI - an international association with a proud history and promising future. On behalf of the Board, I would like to thank Michael Drummond for his willingness to take on the role of Chairman and the great role he has played in helping the association chart its way into the very sound position it is in today.”

Professor Carl Asche was appointed as Deputy Chairman, GENI. Professor Asche is the Executive Director of the Pharmacotherapy Outcomes Research Centre and Research Professor in the Department of Pharmacotherapy at the University of Utah College of Pharmacy, Salt Lake City, USA. Professor Asche said “I am very pleased to move to the Deputy Chairman role to facilitate GENI’s work to drive international mechanisms to integrate clinical guidelines, clinical and cost effectiveness evidence into national decision making and clinical practice. We will continue to effectively forge links with national bodies that set standards, regulation, and funding processes”.

## CEO'S REPORT

Dr Kathryn Antioch, GAICD, PhD (Health Economics) MSc, BA (Hons), AFCHSM, CHM



### (a) COVID-19 pandemic (2020 to 2023)

During the COVID-19 Pandemic, the GENI management team, researchers, Medical Advisory Committee, Board members and the GENI LinkedIn Group continued to work virtually/remotely. This is in accordance with our usual business practices as GENI is an international virtual organisation.

Further, we used telephone or video calls in preference to face to face meetings, to remain available for any work we were progressing and to protect our staff and community as we all worked to contain the spread of the virus. GENI's operations in Australia aligned its work practices in accordance with the restrictions imposed by State and Australian governments. International staff were advised to abide by the pandemic laws and restrictions applicable to their country.

I want to thank you for your personal resilience and commitment to our core culture and values. GENI's vision has never been more important. GENI has over 1,118 affiliate members world-wide. GENI enables health economists, epidemiologists, clinicians, and medical experts world-wide to work with prominent international bodies, health services and governments. You assist to bring this vision to life in the work you do. Australia has been in a sound position geographically, socially, and economically to weather the pandemic storm and we all worked together to carve our own curve. Many of you worked on very important COVID-19 and other health priorities through your daily work in your other roles in leadership, direct patient care in hospitals, planning and monitoring in government departments, consulting firms, national medical associations and in research institutions. Thank you for the work you do!

The work of GENI assisted in the pandemic through stakeholder engagement and the dissemination of published breaking news and systematic reviews on new COVID-19 treatments and vaccinations thereby contributing to the tapestry of emerging evidence. New clinical guidelines were also disseminated. I worked on the economics of the COVID-19 Pandemic: economic evaluation of government mitigation and suppression policies, health system innovations and models of care. I also participated in Australian Senate Inquires on COVID-19 and Fetal Alcohol Spectrum Disorder (FASD). I participated in senate inquiry hearings conducted at Parliament House by invitation of the Senate Committee on the FASD work. My work on economic evaluation models to address COVID was presented at the International Health Economists Association (IHEA) during 2021 and was published in the Journal of Public Health during 2023. Further, the far-reaching impact of COVID shaped GENI's agenda across several areas including those outlined below.

GENI advanced our agenda in other global priorities such as non-communicable diseases in Asia Pacific, vaccinations in Africa, nutrigenomics for mitigating hunger in Africa, prostate cancer, cystic fibrosis, diabetes, Value Based Health Care, Activity Based Funding, exploring funding opportunities, perioperative health economics issues, horizon scanning for new drugs, facilitating interdisciplinary approaches to research, new clinical guidelines and associated methodologies to develop them.

Importantly, we continue to provide opportunities for early career members to gain experience in applied health economics in health services research commencing as Researchers for GENI. To date we have had excellent participation by graduates in medicine, law, economics, health administration, public health, epidemiology, finance and others working in health-related roles. Many have since been promoted to senior management roles on GENI and in their other work roles over the years.

### (b) Clinical Practice Guidelines Innovations Steering Committee (CPGISC), GENI

**Agenda:** The committee was established in 2023. The purpose is to facilitate GENI's agenda to drive international mechanisms to integrate Clinical Practice Guidelines, clinical and cost effectiveness evidence into national decision making and clinical practice. This includes conducting research, publishing results and forging links with national bodies that set standards, regulation, and funding processes such as governments and insurance bodies.

The Steering Committee provides leadership to GENI staff conducting research in four sub-committees investigating and preparing publications concerning CPG development, digital health and AI interventions, Value Based Reimbursement, and health services capital funding and planning. By publishing the findings, GENI will facilitate global reforms by identifying approaches to improve evidenced-based care, along with improvements in equity in related national funding and regulation scenarios. The committee identifies strategies for GENI to forge links with national bodies that set standards, regulation, and funding processes such as governments and insurance bodies to facilitate the implementation of the published research findings.

**Members** Dr Kathryn Antioch (Chair), Prof Carl Asche, Prof Louis Niessen, Prof Paul Myles, Angeline Kuek (Committee Secretary).

#### Leadership for Sub-committee agendas

1. Provide oversight to research by GENI staff in sub-committees investigating and preparing briefing papers, journal articles and books concerning:
  - (a) **Clinical Practice Guideline development and regulation.** Investigate CPG development and regulation processes in the UK, Australia, Canada, USA, the Netherlands, Sweden, Norway and Denmark identifying by literature review for each country:
    - an overview of development processes
    - how economic evaluation evidence is used and related methodologies.
    - methods to grade the economic, clinical and epidemiological evidence and related levels of evidence
    - use of AI and digital health interventions in the development processes.
    - governance processes for clinical guideline approvals by regulatory bodies.
    - evaluations undertaken of the above-mentioned processes used, including recommendations for change
    - best practice lessons identified serving as international models.
  - (b) **Digital health interventions and Artificial Intelligence:** Investigate the use of digital health intervention and AI platforms for clinical practice guidelines globally. Identify best practices that serve as international models.
  - (c) **Value Based Reimbursement:** Investigate policies by governments and other stakeholders in the UK, Australia, Canada, USA, Europe and Asia that use clinical guidelines and other forms of best practice (evidence-based medicine) in funding and reimbursement processes, such as Value Based Reimbursement, to facilitate best practice, cost-effectiveness, and equity in the health system. Identify best practices that serve as international models.
  - (d) **Health services capital funding and planning:** Investigate the use of clinical guidelines and clinical pathways for health services capital funding and planning globally. Capital includes infrastructure, digital health interventions, IT communication systems, AI, and medical equipment. Identify best practices that serve as international models.
2. Identify strategies for GENI to forge links with national bodies that set standards, regulation, and funding processes such as governments and insurance bodies to facilitate the implementation of the published research findings.

The **Value Based Health Care Committee** was established in 2021 and is an important GENI initiative. Committee members have presented several papers at international conferences and published results in the Journal Discover Health Systems (DHS) during 2024. We have investigated pandemic impacts upon VBHC and identified remedial economic and public health policies globally, across all health sectors and in aged care. Members work collaboratively with the Value Based Reimbursement sub-committee of the Clinical Practice Guidelines Innovations Steering Committee. GENI was one of three finalists in the 2024 National Sustainable Healthcare Awards (research) by Bond University and Australasian College of Health Services Management for our DHS Publication.

#### (c) National Health and Medical research Council (NHMRC) reviews - Clinical guideline development (2024 and 2025)

I was pleased to have the opportunity to participate in two major NHMRC reviews concerning clinical guideline development and regulation in Australia. The first review concerned the NHMRC's draft 'Procedures and Requirements for Meeting the NHMRC Standard for Clinical Practice Guidelines (Version 2)', September 2024. The second review concerned NHMRC's 'Guidelines for Guidelines' – The Updating Module. The draft module was released for public consultation during January 2025.

Dr Kathryn Antioch GAICD, PhD, MSc, BA (Hons) AFCHSM, CHM  
Chief Executive Officer,  
Guidelines and Economists Network International (GENI)

## OUR OBJECTIVES AND ACTIVITIES

GENI's aim is to drive international mechanisms to integrate guidelines, clinical and cost effectiveness evidence into national decision making and clinical practice. A key imperative is to forge links with national bodies that set standards, regulation, and funding processes such as governments and insurance bodies.

GENI has a unique focus on achieving both clinical and cost effectiveness in healthcare delivery and equity in related funding world-wide. The current reach of GENI Board member's work is extensive ranging from impacts at the point of health care delivery and extending through to national Governments and Parliaments.

Key conference presentations, other projects, GENI performance awards and selected publications by GENI staff are outlined below:

### Conference presentations by GENI staff

1. September 2025 'Artificial intelligence, digital and virtual health care and clinical practice guidelines: global lessons in evaluation, economics and best practice' Oral Presentation by Dr Antioch at the *2025 Australian Health Economists Society Conference*, Canberra Australia 11 and 12 September 2025 . Antioch K, Asche C, Kuek A, Singh S, Adibi A
2. August 2025 'Australian bundling payment reforms: Facilitating cost-effective and value-based health care for the National Health Reform Agreement (NHRA)' Oral Presentation by John Pilla and Kathryn Antioch at the *Independent Health and Aged Care Pricing Authority (IHACPA) 2025 Conference* Adelaide Australia 5<sup>th</sup> August 2025. Pilla J, Antioch K, Myles P, Khan F
3. July 2025 'New appraisals of economic evaluations of digital diabetes health interventions International Lessons from Bangladesh' Oral presentation by Professors Niessen and Asche at the *International Health Economists Association (IHEA) 2025 World Congress*, Bali Indonesia 22 July 2025 Niessen N, Asche C, Antioch K, Islam S
4. July 2025 'Value Based Health Care (VBHC) for the elderly: Addressing challenges during the pandemic using Multi Criteria Decision Analysis (MCDA)' Oral presentation by Dr Antioch at the *International Health Economists Association (IHEA) 2025 World Congress*, Bali Indonesia 22 July 2025 Antioch K, Pilla J, Kuek A, Marshall R
5. October 2024 'Clinical Practice Guideline (CPG) development and regulatory processes in Australia: International lessons in best practice, clinical governance and VBHC'. Oral presentation by Dr Antioch at the *Australasian College of Health Services Management (ACHSM) 2024 Leadership Congress: 'Sustainability in Health Care'* Brisbane Australia October 2024. (Antioch KM, Warncken D, Asche C, Myles P, Pilla J)
6. September 2024 'Clinical Practice Guideline (CPG) development and regulatory processes in Australia: International lessons in best practice, economic evaluation, clinical governance and Value Based Health Care (VBHC)' Oral presentation by Dr Antioch at the *National Australian Health Economists Society 2024 Congress*, Sydney Australia 19-20 September 2024.(Antioch KM, Warncken D, Asche C, Myles P, Pilla J)
7. August 2023 'Value Based Health Care (VBHC) for the elderly: Addressing challenges during the pandemic using Multi-Criteria Decision Analysis' Oral presentation by Dr Antioch at the *Independent Health and Aged Care Pricing Authority (IHACPA) 9-11 August 2023 Conference* (Antioch KM, Pilla J, Kuek A and Marshall R).
8. August 2023 'Value based reimbursement reform opportunities for Australian public hospitals: enhancing value-based health care' Oral presentation by J Pilla at the *Independent Health and Aged Care Pricing Authority (IHACPA) 9-11 August 2023 Conference* (Pilla J, Antioch KM, Kuek A and Marshall R).
9. May 2022 'The Impact of COVID-19 on Value Based Health Care (VBHC)' *Activity Based Funding (ABF) Conference 5-6 May 2022*. Independent Hospital Pricing Authority (Antioch KM, Kuek, A, Pilla J, Marshall R) Presented by Antioch KM
10. May 2022 'Value Based Health Care Australian developments and opportunities for public hospitals', *Activity Based Funding (ABF) Conference 5-6 May 2022*. Independent Hospital Pricing Authority (Pilla, J, Antioch K, Marshall R, Kuek A) Presented by Pilla J.

11. October 2021 'The COVID-19 Pandemic Challenge for Leaders – Global Lessons on How to Thrive'. Oral presentation at the *Australasian College of Health Service Management (ACHSM) Asia Pacific Health Leadership Congress 13-14 October 2021* (Antioch, KM)
12. July 2021 'The Economics of Pandemics: New Methodologies and Governance to Mitigate Pandemics Globally'. Oral presentation at the *International Health Economics Association (IHEA) 2021 World Congress 12-15 July 2021 Health Economics in Time of Global Change* (Antioch, KM)
13. October 2019 'Practical explorations of how to thrive challenges for health leaders in the public and private sector: Value Based Health Care'. (Oral presentation) *Australasian College of Health Services Management (ACHSM) Asia Pacific Health Leadership Congress 2019*. Gold Coast Australia (Antioch KM)
14. November 2018 'Cost Effectiveness of prostate cancer screening and diagnostic strategies: International Lessons for Clinical Practice Guidelines' Presented at the *National Health and Medical Research Council (NHMRC) Research Translation Symposium 2018* (Poster) (Antioch KM, Asche C, Dugdale P, Schwarz M, Bristow Z, Pan Y, Sherwin F, Kuek, A, Dally M, Anderson N, Wancken D, Richardson L)
15. September 2017 'Effectively leading waves of change in America, Europe, Asia Pacific and Africa: Using health economics, epidemiology, planning and regulation reform' *Workshop for ACHSM/ACHS 2017 Asia-Pacific Congress workshop* (Antioch KM Kerr R, Robinson P and Kerr W)
16. July 2017 'Australian COAG national health reforms 2017-2020 Implications for the private sector. *Annual Health Insurance Summit 2017, Sydney Australia* (Antioch KM Invited presentation)
17. July 2017 'Global Priorities for Clinical Practice Guidelines and Health Policy: Implications of Economic Evidence, Big Data and Personalised Medicine' *IHEA World Congress 2017 Boston USA* Organised Session: (Session participants Antioch KM, Niessen L, Asche C and Lewis M)
18. November and October 2016, 'Activity Based Funding Reform Toolkit 2016: A Practical Approach to Improving Health Service and Hospital Performance in an Environment of Fiscal Constraint (Addressing 2016 COAG Health Reforms)' Two day workshop: Participants from NSW, Victoria, WA, ACT, NT. Workshops conducted in WA and NSW (Antioch, KM – Invited speaker following involvement in two 2016 Senate Inquires on 2016 COAG Health Reforms and Public Hospital Funding).
19. October 2016 'Workshop: Balancing Innovation and Risk: Using Economics, Evidence Based Planning, Communication and Advocacy in Health Policy and Health Services Delivery'. *Joint ACHSM/ACHS Asia-Pacific Congress, 26-28 October, 2016, Brisbane, Australia* (Antioch KM, Kerr R, Atanasova B)
20. November 2016 'Personalised Medicine, Genetics, Economics: Cystic Fibrosis Lessons for Quality, Guidelines and Policy Reforms' *NHMRC Symposium on Research Translation 2016 Melbourne* (Oral presentation by Antioch KM). Poster at October 2016 *Joint ACHSM/ACHS Asia-Pacific Congress, October 2016, Brisbane* (paper by Antioch KM, Wilson J, Bristow Z, Sherwin F, Pan Y, Richardson L )
21. October 2015 'Effective Stakeholder Engagement on Health Issues: Powerful Impacts Q & A' *ACHSM/ACHS Asia Pacific Congress 28-30 October 2015* (Panel participants Antioch KM, Rasa J, Reid M et al.)
22. July 2015 'Systematic review of the Cost Effectiveness Evidence for interventions for Type 2 Diabetes: International Lessons for Clinical Guidelines' Presentation by Antioch KM in Organised Session: *Global Priorities for Economic Evidence in Clinical Practice Guidelines. International Health Economists Association (IHEA) World Congress Italy 2015* (Session Participants: Antioch KM, Drummond, M Niessen, L, Coyte P and Asche C). Also presented by Antioch KM at *Annual Symposium, NHMRC and ACHSM/ACHS Asia Pacific Congress, 2015* (Paper by Antioch, K Dugdale, P Topliss, D, Sinnott H, Bristow, Z, Dally M, Sherwin F, Robson H, Pan Y, Pratt N, Xu N, Wong, K)
23. November 2014 Panel 'Promoting effective clinician and stakeholder engagement' Sydney (Antioch KM) Invited Speaker, Panelist for *3rd Annual Health Technology Assessment Conference, 2014* .
24. May 2014 Invited participation and presentation – *Panelist for Australasian College of Health Service Management (ACHSM) Breakfast Forum 2014 – Live Televised Debate on the Victorian Health Budget 2014-15* (Panelists: Antioch KM, Wallace L et al)

25. July 2013 'Economic Guidelines for Clinical Guidelines: Lessons for Australian Parliament, Governments and Health Services' presentation by Antioch KM, Sydney Australia. *International Health Economists Association (IHEA) World Congress 2013* In Organized session on "Economic Guidelines for Clinical Guidelines" (Session Participants Antioch KM, Drummond M, Neissen L, Peacock S and Vonderling H)
26. October 2011 Panel member on 'Council of Australian Government (COAG), national health reforms through new Health Reform Agreement's and international reforms'. *Australian Financial Review Annual Health Congress, 2011 Sydney* (Antioch KM) Invited speaker.
27. July 2011 'Integrating Economic Evidence, Guidelines and Risk Adjustment into Australian National Health Agreements:2008 & 2010' (Antioch KM) Organized Session 'Implementing Economic Evidence through CPGs: International Experience'. *International Health Economists Association (IHEA) World Congress 2011 Toronto, Canada*. (Session Participants Antioch KM, Drummond M, Niessen L and Lewis M)
28. August 2010, 'Advantages of the National Health and Hospitals Network Agreements (NHHA) 2010: Building on Victoria's success' Presentation at the *National Hospital Reform Summit 16 and 17 August 2010 Melbourne, Australia* (Antioch KM) Invited speaker.
29. December 2009 'Performance and Funding Reforms using Risk Adjustment and Evidence Based Medicine for 2009 National Health Care Agreements (NHAs): Submissions to Australian governments, COAG, Productivity Commission and Reform Commission'. *Hospital Performance Measurement National Summit 10-11 December 2009 Sydney* (Antioch KM) Invited speaker.
30. July 2009 Guidelines and Economists Network International (GENI) Satellite Session and Organised Sessions. Presented papers on *Council of Australian Government (COAG) reforms; Global Financial Crisis; and GENI's Master plan* (Antioch, KM) *International Health Economists Association (IHEA) World Congress 2009 Beijing, China* (Session Participants: Antioch KM Niessen, L, Scott G, Lewis M (World Bank), Tam Torres, T (WHO), Richardson J)
31. November 2007 'Bioterrorism Preparedness: Biological, Radiological and Chemical. An International Approach' *Counter-Terrorism Summit (Australia) Financial Review Conference 2007* (Antioch KM) Invited Speaker. Reported in Australian and International news media.
32. July 2007 Organised session on 'Integrating Economic Evidence into Clinical Practice Guidelines and Practice' and Satellite Session by 'Guidelines and Economists Network International (GENI)'. *International Health Economists Association (IHEA) World Congress 2007 Denmark* (Session Participants Antioch KM, Drummond M, Rutten, F Niessen L et al)
33. May 2007 'Risk Adjustment in Health Financing Internationally' *International Actuarial Association Health Section Colloquium, South Africa 2007* (Antioch KM) Invited speaker.
34. July 2006 'Lessons on Integrating Economic and Clinical Evidence into Clinical Practice'. Workshop for *European Health Economists Association Conference 2006, Budapest, Hungary* (Antioch KM) Invited speaker.
35. October 2005 'Integrating Economic Evidence into Clinical Practice Guidelines' *Cochrane International Colloquium 2005, Melbourne* (Workshop Participants: Antioch KM and Drummond M York and NICE UK) requested by NHMRC (invited speakers).
36. July 2005 Presenter in competitively selected Organised Session 'Integrating Economic Evidence into Clinical Practice Guidelines in the UK, The Netherlands, Australia and USA'. *International Health Economists Association Conference (IHEA) 5<sup>th</sup> World Congress 2005, Barcelona Spain* (Session Participants Antioch KM, Drummond M, Rutten F, Neissen, L)
37. July 2005 'International Uses of Risk Adjustment to Improve Health Care Financing Systems.' Organiser and Presenter in competitively selected Organised Session at the *International Health Economists Association Conference (IHEA) 5<sup>th</sup> World Congress 2005, Barcelona Spain* (Antioch KM, Ellis R et al)
38. June 2005 *Fourth Annual Health Insurance Summit 6-7 June 2005* (Chair 7<sup>th</sup> June) Sydney, Australia. (Antioch KM) invited speaker.
39. September 2004 'Integrating cost effectiveness evidence into CPGs in UK, Netherlands, and Australia' (pre-conference session) Chair and presenter, *European Health Economists Association Conference, 2004 London School of Economics*. (Session Participants Antioch KM, Drummond M, Rutten F)

### Other projects: work by Dr Antioch and other GENI members on the economics of the pandemic published in international journals

- **Antioch, KM** (2023) The economics of the COVID-19 pandemic: economic evaluation of government mitigation and suppression policies, health system innovations, and models of care. *J Public Health (Berl.)* <https://doi.org/10.1007/s10389-023-01919-z>
- **Antioch KM, Kuek A, Pilla J, Marshall R.** A multi-criteria decision analysis framework that prioritizes economic policy to enhance value-based health care during the COVID-19 pandemic. *Discover Health Systems* **3**, 12 (2024). <https://doi.org/10.1007/s44250-024-00070-0>
- **Kuek A, Antioch KM, Robinson, P** (2025). The management of chronic diseases during the SARS-Cov-2 pandemic in WHO Western-Pacific and South-East Asian regions *J Public Health (Berl.)* <https://doi.org/10.1007/s10389-025-02515-z>

### Current high priority projects

See CEO's report for ongoing projects being conducted through sub-committees of the Clinical Practice Guidelines Innovations Steering Committee (CPGISC). These include:

- Clinical Practice Guideline development and regulation. Investigate CPG development and regulation processes in the UK, Australia, Canada, USA, the Netherlands, Sweden, Norway and Denmark
- Digital health interventions and Artificial Intelligence
- Value Based Reimbursement
- Value Based Health Care
- Health services capital funding and planning

### Future high priority projects

New committees will be established under the auspices of the CPG Innovations Steering Committee during 2026, including:

- 'Novel evaluation methods in health economics' to investigate sustainability, Integrated care models, end of life, non-communicable diseases, regional QoL utility weights for South Africa, Pacific and Asia, and Multi Criteria Decision Analysis (MCDA).
- 'MCDA applications for vaccine development and implementation during pandemics'.
- 'Pandemic preparedness' for global emerging virus threats such as Influenza A virus subtype H5N1 (H5N1) and Pipistrellus bat coronavirus HKU5 - HKU5-CoV-2 (HKU5)

### Earlier projects

- Africa COVID-19 vaccine project by Antioch K, Sherwin F, Robinson P.
- Cost Effectiveness Analysis of Child Vaccinations in Africa: International Lessons for Clinical Practice Guidelines in Developing Countries by Antioch K, Kuek A, Sherwin F, Anderson N, Richardson L, Robinson P, Pan Y, Daghagh S, Maden J, Meyerowitz-Katz G, Warncken D, Khan F.

### Briefings for the CEO

- Research into the Australian Charitable Accounting Standards relating to Annual Reports by Seidel, D.
- Funding opportunities for research concerning COVID-19 in Australia and internationally; Summary of Australian Government specifications for categories of research funding; the Export Market Development Grants scheme (EMDG); the Medical Research Future Fund (MRFF); New drug applications under the Pharmaceutical Benefits Scheme (PBS) for a drug to treat Spinal Muscular Atrophy; Developments concerning Oncotype DX breast cancer assay by Seidel, D
- Review of funding opportunities for Non-communicable Diseases (NCD) crisis in the Asia-Pacific by Antanasova B
- International health funding opportunities for GENI by Chalise, B.
- Nutrigenomics for mitigating hunger in Africa by Richardson L

### Collaborations with Alfred Health and ADMA

- Clinical guidelines through a collaboration between ADMA and GENI, through the Alfred Health Volunteer Program (2012-2013) Antioch K, Sinnott H, Richardson L, Parker C

### Public Relations: GENI website development and maintenance

- Facilitate international collaboration by Bristow Z (to 2019) and Anderson, N (since 2019).





GENI staff presented three papers at the Independent Health and Aged Care Pricing Authority (IHACPA) conference, Brisbane Queensland in 2023. From left John Pilla Executive Director, Health Funding Policy and Program Evaluation; Dr Rhonda Kerr Executive Director Executive Director, Economics, Health Services and Planning and Dr Kathryn Antioch, Chief Executive Officer, GENI.



Dr Kathryn Antioch, Chief Executive Officer, GENI presented 'Clinical Practice Guideline (CPG) development and regulatory processes in Australia: International lessons in best practice, clinical governance and VBHC' at ACHSM 2024 Leadership Congress: 'Sustainability in Health Care' Brisbane Australia October 2024. Co-authors are Dr David Warncken, Professor Carl Asche, Professor Paul Myles and John Pilla.

## Looking to a visionary future

Independent Health and Aged Care Pricing Authority 2025 Conference, Adelaide SA.



Dr Kathryn Antioch  
Chief Executive Officer, GENI



John Pilla  
Exec Dir, Health Funding Policy & Program Evaluation

GENI had a strong presence at the 2025 Independent Health and Aged Care Pricing Authority (IHACPA) conference, Adelaide SA, August.

John Pilla, Executive Director, Health Funding Policy and Program Evaluation, GENI and Dr Kathryn Antioch CEO, GENI co-presented: "Australian bundling payment reforms: Facilitating cost-effective and value-based healthcare for the National Health Reform Agreements".

They reported that international bundling payment reforms have provided promising but variable impacts on quality, costs and practice change. These were impacted by the policy imperative, implementation context, operational characteristics and incentives.

Model variations involved inclusions in the bundled package, bundle period, historical model being replaced, risk adjustment methods, financial risk sharing, and supporting mechanisms to drive change. These findings were echoed by three international speakers at the conference!

Their co-authors provide vital stakeholder engagement, clinical, operational and implementation perspectives on bundling payment reforms in Australia. They are members of GENI's Medical Advisory Committee, including Prof Paul Myles Head of Alfred Health's and Monash University's Department of Anaesthesiology and Perioperative Medicine and Prof Fary Khan, Director of Rehabilitation Services, Royal Melbourne Hospital, Clinical Professor, Department of Medicine, University of Melbourne.

The work involves the policy and research agenda of GENI's Value Based Health Care (VBHC) and Value Based Reimbursement (VBR) Committees. It builds upon GENI's work recently published in the following two international journals concerning the COVID-19, the pandemic, VBHC and economics (Antioch, 2023; Antioch, Kuek, Pilla and Marshall, 2024)

## International Health Economists Association (IHEA) 2025 Conference, Bali Indonesia

Unveiling elegant global aged care policy solutions and expediting global digital health economic evaluations.



Dr Kathryn Antioch, CEO, GENI and Prof Carl Asche, Deputy Chairman, GENI Board after the Board meeting

The GENI had a strong presence at the 2025 IHEA World Congress in Bali Indonesia during July. During the conference, several papers were presented and moderated by GENI Board members, including the GENI CEO, and a very productive GENI Board meeting was conducted.

Presenters included Dr Kathryn Antioch, Professors Louis Niessen, and Carl Asche. The two conference papers presented included, firstly “Value Based Health Care (VBHC) for the elderly: Addressing challenges during the pandemic using Multi-Criteria Decision Analysis” Authors include GENI’s CEO, Board member and presenter Dr. Kathryn Antioch, John Pilla, Angeline Kuek, and Rick Marshall. Elegant solutions discussed in the presentation involve new social risk adjustment and frailty risk indexes from UK, Canada, China, Finland, The Netherlands, Australia; Norway’s holistic continuity of patient care pathway; USA Medicare palliative care homebound program; genetic research to slow ageing!

The other conference presentation was entitled “Appraisal of Economic Evaluations of Digital Health Interventions in Type 2 Diabetes: International Lessons from Bangladesh”. Authors include GENI’s Chairman Louis Niessen, Deputy Chairman Carl Asche, and CEO Kathryn Antioch. Both studies support the efforts by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Consolidated Health Economic Evaluation Reporting Standards for Digital Health Interventions (CHEERS-DHI) Working Group and the GENI Digital Health Interventions and Artificial Intelligence Committee to establish standardized economic evaluation methods for digital health and AI interventions.

Prof Louis Niessen moderated nine presentations in the session “Technological Advances in Data, Digital, and Telehealth” Field of supply and regulation of health services and products. Prof Carl Asche moderated five presentations in the session “Within Trial Economic Evaluations” Field of economic evaluation of health and related care interventions.

The aged care work involves the policy and research agenda of GENI’s VBHC and Value Based Reimbursement (VBR) Committees. It builds on GENI’s work recently published in two international journals about COVID-19 pandemic, VBHC and economics (Antioch, 2023; Antioch, Kuek, Pilla and Marshall, 2024).

## Australian Health Economists Society 2025 Conference, Canberra

Unveiling elegant AI and Digital Health evaluations, AI regulations and their implications for clinical guidelines.



Dr Kathryn Antioch, CEO GENI

GENI had a strong presence at the 2025 Australian Health Economists Society (AHES) Conference, located at the old Parliament House, Canberra, ACT, Australia. The paper presented by Dr Kathryn Antioch was entitled: 'AI, Digital and Virtual Healthcare and Clinical Practice Guidelines (CPGs): Global Lessons in AI and Digital Health evaluations for CPGs'. Her presentation discussed :

- a review of the use of AI and DHIs for CPGs to identify evaluation issues, best practice and digital health models.
- decision-making tools, ethics, CPG electronic platforms, economic implications of AI and digital health, use of AI in health economics and outcomes research (HEOR) and AI regulation.
- GENI's collaboration with ISPOR's Consolidated Health Economic Evaluation Reporting Standards for DHI (CHEERS-DHI) Working Group to develop the CHEERS-DHI standards checklist.
- Global healthcare AI regulatory landscape for USA, UK, EU, Canada, China, Latin America and Africa.
- recommendations for peak bodies to participate in the Australian Government's 'Safe and Responsible AI in Health Care Legislation and Regulation Review'.

Co-authors include Prof Carl Asche, Deputy Chairman GENI Board, Angeline Kuek, Executive Director International Health Reforms, GENI, Dr Symret Singh, Senior Project Manager, GENI and Sasan Adibi, Director, Digital Health Interventions and Artificial Intelligence, GENI.



GENI staff at the Australasian College of Health Services Management (ACHSM) congress in earlier years. From left Fiona Sherwin, Priscilla Robinson, Kathryn Antioch and Angeline Kuek

## PERFORMANCE AWARDS by the CEO and Board Chairman

### Guidelines and Economists Network International (GENI) Award for Outstanding Contribution recipients

	Year awarded	GENI /professional position*	Qualifications
	2025	Director, Digital Health Interventions and Artificial Intelligence  CEO, Founder Research Vitality	PhD Communications and Information Systems (University of Waterloo Canada), MSc (University of Windsor Canada) MSc (Brunel University UK)
Dr Sasan Adibi			
	2024	Executive Director, Economics, Health Services and Planning  Director, Rhonda Kerr and Assoc. Health Planning	B.A (Economics) ANU; GAICD 2009; Doctor of Philosophy (Ph.D.) Curtin University.
Dr Rhonda Kerr			
	2023	Executive Director, Radiation Oncology and Clinical Guidelines  Radiation Therapy Manager, Austin Health	Doctor of Philosophy (PhD) Monash University; Ba App. Sci (Medical Radiations) RMIT; Ba App Sci (Human Biology) RMIT
Nigel Anderson			
	2022	Director, Health Funding Policy, and Program Evaluation  Director, Uneek Consulting	Bachelor of Science (Hons), (University of Adelaide), Graduate Diploma in Business Administration, (University of South Australia) Member and Committee Chair, Australasian Evaluation Society
John Pilla			

	2021	Director, International Health, and Epidemiology	PhD Epidemiology (Melbourne University), MPH (Monash University), MHS (Public Health Practice) (La Trobe University)
Dr Priscilla Robinson		Adjunct Associate Professor, School of Public Health, La Trobe University	
	2020	Senior Project Manager, GENI	Master of Business Law (MBL) (Southern Cross University), Bachelor of Accounting (BAcc) (University of South Australia), Diploma of Commerce (SIBT/Macquarie University), Diploma of Business Administration (Williams Business College)
Denise Seidel		Research and Consulting Manager, Transdisciplinary (TD) School, UTS	
	2019	Senior Project Manager, GENI	Bachelor of Health Science (BHSc) (Victoria University), Bachelor of Medical Science (BMedSc) (Hons) (University of New South Wales), Master of Public Health (MPH)/ Global Health candidate (University of New South Wales).
Lauren Richardson		Senior Policy Officer, Screening and Cancer Prevention, Department of Health and Human Services.	
	2018	Director, Allied and Community Health	B Physio (Hons) (Melbourne University) G Cert Public Health (Flinders University) MHA (La Trobe University) MBA (Melbourne University) FCHSM
Fiona Sherwin		Senior Project Officer, Office of the Chief Executive, Monash Health	
	2017	Director, International Health Reforms, GENI	B BiomedSc (University of Melbourne), BSc (Hons) (University of Melbourne), Master of Public Health (University of Adelaide), Master of Health Administration (La Trobe University).
Angeline Kuek		Senior consultant, KPMG, Health, Ageing and Human Services	
Zoe Bristow	2016	Director, Epidemiology and Clinical Guidelines	Masters Commerce, University of Sydney Masters Public Health, La Trobe University Masters, Epidemiology Uni of Melbourne

\* GENI and professional positions listed above were at the time of the Award.



## GENI MEMBERS' SELECTED PUBLICATIONS

The following selected publications relate to the research roles by GENI's members (bolded). These publications are not necessarily attributed with GENI. For a full list of each member's publications please refer to their GENI profiles online.

1. Abushanab,D, Al-Badriyeh, D **Liew, D** et al (2025) Unravelling the future productivity burden of cardiovascular disease in Qatar: Investigating the modifiable risk factors control in type 2 diabetes, American Journal of Preventive Cardiology, Volume 22, 100961,ISSN 2666-6677, <https://doi.org/10.1016/j.ajpc.2025.100961>.
2. **Adibi, S.** Rajjabifard, D. Shojaei, N. Wickramasinghe (2024) Enhancing Healthcare through Sensor-Enabled Digital Twins in Smart Environments: A Comprehensive Analysis, published in the Special Issue of Sensor-Enabled Digital Twins for Healthcare Applications, MDPI Sensors, on April 27, 2024 <https://www.mdpi.com/1424-8220/24/9/2793>
3. **Adibi, S.** Valizadeh-Haghi, Y. Khazaal, S. Rahmatizadeh (2024) Editorial Mobile Health Application in Addictive Disorders Therapy, Mobile Health Application in Addictive Disorders Therapy, section of Frontiers in Psychiatry on January 24, 2024 <https://pubmed.ncbi.nlm.nih.gov/38370560/>
4. Agyeman AA, Chin KL, Landersdorfer CB, **Liew D**, Ofori-Asenso R (2020) Smell and Taste Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis. Mayo Clin Proc. Aug;95(8):1621-1631. doi: 10.1016/j.mayocp.2020.05.030. Epub 2020 Jun 6. <https://pubmed.ncbi.nlm.nih.gov/32753137/>

5. Alston P, **Myles PS**, Ranucci M (2015) (editors). Oxford Textbooks in Anaesthesia: Cardiothoracic Anaesthesia. Oxford University Press.
6. Amatya B, Elmalik A, Lee SY, Song K, Galea M, **Khan F** (2022) A process evaluation of patient care needs using the Post-Stroke Checklist: A prospective study. *J Rehabil Med.* Feb 14;54:jrm00259 doi:10.2340/jrm.v53.349  
<https://pubmed.ncbi.nlm.nih.gov/35001136/>
7. Amatya B, Elmalik A, Song K, Lee SY, Galea MP, **Khan F** (2022) Responsiveness of the International Classification of Functioning, Disability and Health (ICF) Clinical Functioning Information Tool (ClinFIT) in Routine Clinical Practice in an Australian Inpatient Rehabilitation Setting. *J Rehabil Med.* Apr 20;54:jrm00268. doi: 10.2340/jrm.v54.159 <https://pubmed.ncbi.nlm.nih.gov/35174870/>
8. Amatya, B., and **F. Khan** (2025) Which Prognostic Models Best Predict Clinical Disease Progression, Worsening, and Activity in People with Multiple Sclerosis? A Cochrane Review Summary with Commentary. *NeuroRehabilitation*, vol. 56, no. 1,  
<https://doi.org/10.1177/10538135241303581>
9. Anderson M, Pitchforth E, Asa ria, M, Brayne C, Casadei B, Charlesworth A, Coulter A, Franklin BD, Donaldson C, **Drummond M**, Dunnell K, Foster M, Hussey R, Johnson P, Johnston-Webber C, Knapp M, Lavery G, Longley M, Clark JM, Majeed A et al (2021) LSE-Lancet Commission on the future of the NHS: re-laying the foundations for an equitable and efficient health and care service after COVID-19, *The Lancet*, 397, 10288, p 1915-1978 64 p. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(21\)00232-4/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00232-4/fulltext)
10. **Anderson N**, Thompson, Andrews J et al, (2020) Planning for a Pandemic: Mitigating Risk to Radiation Therapy Service Delivery in the COVID-19 Era. *Journal of Medical Radiation Sciences*; 1-6 <https://pubmed.ncbi.nlm.nih.gov/32567800/>
11. Anderson KE, Sahu M, DiStefano MJ, **Asche CV**, Mattingly TJ (2024) 2nd. Pharmacy Closures and Anticonvulsant Medication Prescription Fills. *JAMA.* Dec 3;332(21):1847-1849. doi: 10.1001/jama.2024.19993. <https://pubmed.ncbi.nlm.nih.gov/39495537/>
12. **Antioch, KM.** (2024) Submission to the Australian Commonwealth Government COVID-19 Response Inquiry, Department of Prime Minister and Cabinet. <https://www.pmc.gov.au/sites/default/files/submissions/PMC-CGCR1-2023-0032.pdf>
13. **Antioch KM, Kuek A, Pilla J, Marshall R.** A multi-criteria decision analysis framework that prioritizes economic policy to enhance value-based health care during the COVID-19 pandemic. *Discover Health Systems* **3**, 12 (2024). <https://doi.org/10.1007/s44250-024-00070-0>
14. **Antioch, KM** (2023) The economics of the COVID-19 pandemic: economic evaluation of government mitigation and suppression policies, health system innovations, and models of care. *J Public Health (Berl.)* <https://doi.org/10.1007/s10389-023-01919-z>
15. **Antioch, KM** (2020) Submission to the Senate Select Committee on COVID-19 Inquiry into the Australian Government's Response to the COVID-19 Pandemic Submission No 511 (Published by Parliament)  
[https://www.aph.gov.au/Parliamentary\\_Business/Committees/Senate/COVID-19/COVID19/Submissions](https://www.aph.gov.au/Parliamentary_Business/Committees/Senate/COVID-19/COVID19/Submissions)
16. **Antioch, KM** (2019) Submission to the Senate Community Affairs References Committee Inquiry into Effective Approaches to Prevention, Diagnosis and Support for Fetal Alcohol Spectrum Disorder Submission No 48. (Published by Parliament).  
[https://www.aph.gov.au/Parliamentary\\_Business/Committees/Senate/Community\\_Affairs/FetalAlcoholSpectrumDi/Submissions](https://www.aph.gov.au/Parliamentary_Business/Committees/Senate/Community_Affairs/FetalAlcoholSpectrumDi/Submissions)
17. **Antioch KM, Drummond M, Niessen L, Vondeling, H** (2017) 'International Lessons in New Methods for Grading and Integrating Cost Effectiveness Evidence into Clinical Practice Guidelines' *Cost Effectiveness and Resource Allocation Journal.* 15:1 pages 1-15 <https://resource-allocation.biomedcentral.com/articles/10.1186/s12962-017-0063-x>

18. **Antioch KM**, Ellis RP, Gillett S, Borovnicar, D, **Marshall, R** (2007) 'Risk adjustment Policy Options for Casemix Funding: International Lessons in Financing Reforms' *European Journal of Health Economics* 8(3): 195-212  
<https://pubmed.ncbi.nlm.nih.gov/17273852/>
19. **Antioch KM** and Walsh MK (2004) 'Risk adjusted Vision Beyond Casemix (DRG) Funding in Australia: International Lessons in High Complexity and Capitation' *European Journal of Health Economics*.5: 95-109 <https://pubmed.ncbi.nlm.nih.gov/15452744/>
20. **Antioch KM**, Jennings G, Botti M, Chapman R, Wulfsohn V (2002) Integrating cost-effectiveness evidence into clinical practice guidelines in Australia for acute myocardial infarction. *Eur J Health Econ.*;3(1):26-39. doi: 10.1007/s10198-001-0088-z. <https://pubmed.ncbi.nlm.nih.gov/15609115/>
21. **Asche C**, Almoujahed MO, Ahmad S, Dwyer A, de Ramirez SS (2021) Development of a COVID-19 Patient Registry in Central Illinois. *Narrat Inq Bioeth.*;11(1):E7-E9. doi: 10.1353/nib.2021.0016. <https://pubmed.ncbi.nlm.nih.gov/34334447/>
22. Atlantis, E, Kormas, N, Samaras, K et al. (co-author **Dugdale, P**) (2018), Clinical Obesity Services in Public Hospitals in Australia: a position statement based on expert consensus, *Clinical Obesity*, vol. 8, no. 3, pp. 203-210. <https://pubmed.ncbi.nlm.nih.gov/29683555/>
23. Baltussen R, **Niessen L**. (2006) Priority setting of health interventions: the need for multi-criteria decision analysis. *Cost Eff Resour Alloc.* Aug 21;4:14. doi: 10.1186/1478-7547-4-14 <https://pubmed.ncbi.nlm.nih.gov/16923181/>
24. Barclay E, **Ojo I**, Hake A, Oyenuga A, Satrom K, Lund T, Oyenuga M, Slusher T, Gbadero D (2022) Neonatal Jaundice: Knowledge and Practices of Healthcare Providers and Trainees in Southwest Nigeria. *Am J Trop Med Hyg.* Jun 27;107(2):328–35. doi: 10.4269/ajtmh.21-0588. Epub ahead of print. <https://pubmed.ncbi.nlm.nih.gov/35895425/>
25. Bastani, A., Ayala, A. M. C., Lizama, L. E. C., Elmalik, A., Amatya, B., **Khan, F.**, & Galea, M. P. (2024). Sedentary Behavior and Physical Activity Assessment Following Botulinum Toxin A Treatment in Stroke Patients: A Comparative Pilot Study. *Journal of Stroke Medicine*, 7(2). <https://doi.org/10.1177/25166085241309700>
26. Bhattacharyya S, Hariprasad SM, Albin TA, Dutta SK, **John D**, Padula WV, Harrison D, Joseph G (2022) Suprachoroidal Injection of Triamcinolone Acetonide Injectable Suspension for the Treatment of Macular Edema Associated With Uveitis in the United States: A Cost-Effectiveness Analysis. *Value Health.* Oct;25(10):1705-1716. doi: 10.1016/j.jval.2022.07.008. Epub 2022 Aug 31. <https://pubmed.ncbi.nlm.nih.gov/36055922/>
27. Buhl, R Bel E, Bourdin A, Dávila I, **Douglass J** et al.( 2022) Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion. *Journal of Allergy and Clinical Immunology: In Practice*, Elsevier, 10 (2), pp.422-432. 10.1016/j.jaip.2021.10.059 . hal-03425748v2 <https://pubmed.ncbi.nlm.nih.gov/34763123/>
28. Burrell A, Zrubka Z, Champion A, Zah V, Vinuesa L, Holtorf AP, Di Bidino R, Earla JR, Entwistle J, Boltyenkov AT, Braileanu G, Kolasa K, Roydhouse J, **Asche C** (2022) ISPOR Digital Health Special Interest Group Key Project. How Useful Are Digital Health Terms for Outcomes Research? An ISPOR Special Interest Group Report. *Value Health.* ;25(9):1469-1479. doi: 10.1016/j.jval.2022.04.1730. <https://pubmed.ncbi.nlm.nih.gov/36049797/>
29. Christiani, Y, **Dugdale, P**, Tavener, M et al. (2017), 'The dynamic of non-communicable disease control policy in Indonesia', *Australian Health Review*, vol. 41, no. 2, pp. 207-213. <https://pubmed.ncbi.nlm.nih.gov/27209156/>
30. Couch DL, **Robinson P**, Komesaroff PA. (2020) COVID-19-Extending Surveillance and the Panopticon. *J Bioeth Inq.* Dec;17(4):809-814. doi: 10.1007/s11673-020-10036-5. Epub 2020 Aug 25. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445799/>

31. Crook, J., Blanchard, P., Ciezki, J., Merrick, G., **Millar, J.**, Keyes, M., Tang, C., Stock, R., Song, D., & Frank, S. J. (2025). PACE-B: Where does this position SBRT as an option for localized prostate cancer? *Radiotherapy and Oncology*, 206, Article 110793. <https://doi.org/10.1016/j.radonc.2025.110793>
32. **Daghagh Yazd S**, Wheeler, SA , Zuo, A. (2020). Understanding the impacts of water scarcity and socio-economic farm demographics on farmer mental health in the Murray-Darling Basin, published in *Ecological Economics*, doi.org/10.1016/j.ecolecon.2019.106564 <https://ideas.repec.org/a/eee/ecolec/v169y2020ics0921800919302368.html>
33. De Luca, J., Vogrin, S., Holmes, N., Reynolds, G., Waldron, J., Cox, F., Nazareth, J., Guha, R., Douglas, N., Hardidge, A., Peel, T., **Douglass, J.**, Johnson, D., & Trubiano, J. (2025). Perioperative Penicillin and Cephalosporin Antibiotic Allergy Assessment and Testing The PREPARE Pilot Randomized Clinical Trial. *JAMA Surgery*. <https://doi.org/10.1001/jamasurg.2025.0279>
34. Dunbar, S., **Liew, D.**, Ilomaki, J., & Talic, S. (2025). Overall medicine burden for people on lipid-lowering therapy: Cross-sectional analysis of national pharmacy dispensing data. *Australian Journal of General Practice*, 54(4), 222–228. <https://search.informit.org/doi/10.3316/informit.T2025041500001100029417274>
35. Goh, S.H., Batchelor, R., Dinh, D., Brennan, A., Peters, S., Stub, D., Reid, C., Chan, W., **Liew, D.**, Wilson, W., Lefkovits, J. (2025), Dual Antiplatelet Therapy Prior to Percutaneous Coronary Intervention for Acute Coronary Syndrome: Prevalence and Outcomes in Contemporary Practice. *Catheterization and Cardiovascular Interventions*. <https://doi.org/10.1002/ccd.31520>
36. Hall, A. J. H., & **Topliss, D. J.** (2022). Medical and surgical treatment of thyroid eye disease. *Internal Medicine Journal*, 52(1), 14-20. <https://doi.org/10.1111/imj.15067>
37. Hamblin PS, Sheehan PM, Allan C, Houlihan CA, Lu ZX, Forehan SP, **Topliss DJ**, Gilfillan C, Krishnamurthy B, Renouf D, Sztal-Mazer S, Varadarajan S (2019) Subclinical hypothyroidism during pregnancy: the Melbourne public hospitals consensus. *Intern Med J*. Aug;49(8):994-1000. doi: 10.1111/imj.14210. <https://pubmed.ncbi.nlm.nih.gov/30561039/>
38. Hanafin PO, Sermet-Gaudelus I, Griese M, Kappler M, Ellemunter H, Schwarz C, **Wilson J**, Tan M, Velkov T, Rao GG, Schneider-Futschik EK (2021) Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis. *Front. Pharmacol*. 12:577263. doi: 10.3389/fphar.2021.577263 <https://pubmed.ncbi.nlm.nih.gov/34408649/>
39. Hariprasad SM, Holz FG, **Asche CV**, Issa A, Mora O, Keady S, Rezk MF, Sarocco P, Simoens S. (2025) Clinical and Socioeconomic Burden of Retinal Diseases: Can Biosimilars Add Value? A Narrative Review. *Ophthalmol Ther*. Apr;14(4):621-641. doi: 10.1007/s40123-025-01104-3. Epub 2025 Feb 26 <https://link.springer.com/article/10.1007/s40123-025-01104-3>
40. Idrose NS, Lodge CJ, Erbas B, **Douglass J A**, Bui DS, Dharmage SC (2022) A Review of the Respiratory Health Burden Attributable to Short-Term Exposure to Pollen. *Int. J. Environ. Res. Public Health* 19,7541. <https://pubmed.ncbi.nlm.nih.gov/35742795/>
41. Idrose, N., Vicendese, D., Walters, E., Perret, J., Koplin, J., **Douglass, J.**, Tham, R., Frith, P., Bui, D., Lowe, A., Abramson, M., Bowatte, G., Erbas, B., Knibbs, L., Senaratna, C., Lodge, C., & Dharmage, S. (2025). Multiple at-risk groups have lower lung function during the grass pollen season. *Allergology International*. <https://doi.org/10.1016/j.alit.2025.02.003>
42. Jackson J, **Anderson N**, Wada M et al (2020) Clinical and dosimetric risk stratification for patients at high-risk of feeding tube use during definitive IMRT for head and neck cancer. *Technical Innovations & Patient Support in Radiation Oncology*; 14: 1-10 <https://pubmed.ncbi.nlm.nih.gov/32154393/>

43. **Kerr, R.** Time for a revolution in funding public hospital capacity. (2022) MJA Insight. 28 November, 2022. <https://insightplus.mja.com.au/2022/46/time-for-a-revolution-in-funding-public-hospital-capacity/>
44. **Kerr, R.** Expect big changes for hospital projects after Covid 19. (2022) The Built Environment Economist Australia and New Zealand March 2022 [https://issuu.com/aigs\\_be/docs/bee22mar\\_v2](https://issuu.com/aigs_be/docs/bee22mar_v2)
45. **Kerr R** and Hendrie DV (2018) Is Capital Investment in Australian Hospitals Effectively Funding Patient Access to Efficient Public Hospital Care? Australian Health Review 42 (5): 501-513. <https://pubmed.ncbi.nlm.nih.gov/30135003/>
46. **Kerr R**, Hendrie DV, Moorin RE (2014) Investing in Acute Health Services: Is It Time to Change the Paradigm? *Australian Health Review* 38 (5): 533-40. DOI: 10.1071/AH13226. <https://pubmed.ncbi.nlm.nih.gov/25164470/>
47. Kohli MA, Maschio M, Mould-Quevedo JF, Ashraf M, **Drummond MF**, Weinstein MC (2021) The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom. *Vaccines (Basel)* Jun 4;9(6):598. doi: 10.3390/vaccines9060598. <https://pubmed.ncbi.nlm.nih.gov/34199912/>
48. **Kuek A** and Hakkennes S (2020) Healthcare Staff Digital Literacy Levels and Their Attitudes Towards Information Systems. *Health Informatics Journal*. <https://pubmed.ncbi.nlm.nih.gov/30983476/>
49. **Kuek A, Antioch KM, Robinson, P** (2025). The management of chronic diseases during the SARS-Cov-2 pandemic in WHO Western-Pacific and South-East Asian regions *J Public Health (Berl.)* <https://doi.org/10.1007/s10389-025-02515-z>
50. Lawrence DS, Muthoga C, Meya DB, and et al (co-author **Niessen L**) (2022) AMBITION Study Group. Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in sub-Saharan Africa: an economic analysis of the AMBITION-cm trial. *Lancet Glob Health.*;10(12):e1845-e1854. doi:10.1016/S2214-109X(22)00450-8. <https://pubmed.ncbi.nlm.nih.gov/36400090/>
51. **Lewis M** (2019) We Need to Measure and Address Corruption and Poor Governance in Health Systems Comment on We Need to Talk About Corruption in Health Systems. *Int J Health Policy Manag.* Oct 1;8(10):616-619. doi: 10.15171/ijhpm.2019.44. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819622/>
52. **Lewis M** and Medici A (2019) Health Policy and Finance Challenges in Latin America and the Caribbean: An Economic Perspective. *Oxford Research Encyclopedia of Economics and Finance*. <https://oxfordre.com/economics/display/10.1093/acrefore/9780190625979.001.0001/acrefore-9780190625979-e-246>
53. Lopez, D., Lodge, C., Bui, D., Waidyatillake, N., Su, J., Knibbs, L., Wijesuriya, R., Perrett, K., Koplin, J., Soriano, V., Lycett, K., Wang, Y., Allen, K., Mavoia, S., Dharmage, S., Lowe, A., Peters, R., Cranswick, N., Smart, J. **Douglass J.A.** ... Dure, N. (2024). Air pollution is associated with persistent peanut allergy in the first 10 years. *Journal of Allergy and Clinical Immunology*, 154(6). <https://doi.org/10.1016/j.jaci.2024.08.018>
54. McCaffrey N, Higgins J, Greenhalgh E, White SL, Graves N, **Myles PS**, Cunningham JE, Dean E, Doncovio S, Briggs L, Lal A (2022) A systematic review of economic evaluations of preoperative smoking cessation for preventing surgical complications. *International Journal of Surgery*, 104, [106742]. <https://doi.org/10.1016/j.ijsu.2022.106742>
55. Mcilroy, D. R., Feng, X., Shotwell, M., Wallace, S., Bellomo, R., Garg, A. X., Leslie, K., Peyton, P., Story, D., & **Myles, P. S.** (2024). Candidate Kidney Protective Strategies for Patients Undergoing Major Abdominal Surgery: A Secondary Analysis of the RELIEF Trial Cohort. *Anesthesiology*, 140(6), 1111-1125. <https://doi.org/10.1097/ALN.0000000000004957>

56. Mcilroy, D. R., Wettig, P., Burton, J., Neylan, A., French, B., Lin, E., Hastings, S., Waldron, B. J. F., Buckland, M. R., & **Myles, P. S.** (2024). Poor Agreement Between Preoperative Transthoracic Echocardiography and Intraoperative Transesophageal Echocardiography for Grading Diastolic Dysfunction. *Anesthesia and Analgesia*, *138*(1), 123-133. <https://doi.org/10.1213/ANE.0000000000006734>
57. Morton, J.I., **Liew, D.**, Watts, G.F. *et al.* (2025) Immediate Versus 5-Year Risk-Guided Initiation of Treatment for Primary prevention of cardiovascular disease for Australians Aged 40 Years: A Health Economic Analysis. *PharmacoEconomics* *43*, 331–349. <https://doi.org/10.1007/s40273-024-01454-z>
58. Morton, JI, **Liew, D.**, Watts, GF., Zoungas, S., Nicholls, SJ Dixon, P *et al* Rethinking cardiovascular prevention: cost-effective cholesterol lowering for statin-intolerant patients in Australia and the UK, *European Journal of Preventive Cardiology*, 2025;; zwaf114, <https://doi.org/10.1093/eurjpc/zwaf114>
59. Moses, C **Adibi, S.** Islam, S. Angelova M (2023) Time-domain heart rate variability features for automatic congestive heart failure prediction, published in Wiley’s ESC Heart Failure, on November 27, 2023 <https://pubmed.ncbi.nlm.nih.gov/38009405/>
60. Moses, C **Adibi, S** Wickramasinghe, N Nguyen, L. Angelova, M Islam S (2023) Non-invasive blood glucose monitoring technology in diabetes management: Review, published in the mHealth, AME Publishing Company, on October 7, 2023 <https://pubmed.ncbi.nlm.nih.gov/38323150/>
61. **Myles, P. S.**, Corcoran, T. B., Chan, M. T., Asghari-Jafarabadi, M., Wu, W. K. K., Peyton, P., Leslie, K., & Forbes, A. (2024). Intraoperative dexamethasone and chronic postsurgical pain: a propensity score-matched analysis of a large trial. *British Journal of Anaesthesia*, *133*(1), 103-110. <https://doi.org/10.1016/j.bja.2023.12.031>
62. Ng E, **Topliss DJ**, Paraskeva M, Paul E, Sztal-Mazer S (2021) The Utility of Prophylactic Zoledronic Acid in Patients Undergoing Lung Transplantation. *J Clin Densitom.* Oct-Dec;24(4):581-590. doi: 10.1016/j.jocd.2020.10.003. Epub 2020 Oct 21. <https://pubmed.ncbi.nlm.nih.gov/33189560/>
63. Ngwira, L. G., Maheswaran, H., Petrou, S., **Niessen, L.**, & Smith, S. C. (2024). Cross-cultural adaptation and psychometric validation of the Chichewa (Malawi) PedsQLTM 4.0 Generic Core Scales child self-report and PedsQLTM 4.0 GCS teen self-report. In *Quality-of-Life Research* (Vol. 33, pp. S133-S133). VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS: SPRINGER. <https://pubmed.ncbi.nlm.nih.gov/39254899/>
64. Ngwira, L.G., Maheswaran, H., Petrou, S. **Niessen L et al.** Cross-cultural adaptation and psychometric validation of the Chichewa (Malawi) PedsQL™ 4.0 Generic Core Scales child self-report and PedsQL™ 4.0 GCS teen self-report. *J Patient Rep Outcomes* *8*, 103 (2024). <https://doi.org/10.1186/s41687-024-00761-5>
65. Ngwira, L.G., Maheswaran, H., Verstraete, J Petrou, S **Niessen, L. et al.** Psychometric performance of the Chichewa versions of the EQ-5D-Y-3L and EQ-5D-Y-5L among healthy and sick children and adolescents in Malawi. *J Patient Rep Outcomes* *7*, 22 (2023). <https://doi.org/10.1186/s41687-023-00560-4>

66. Ong WL, Thangasamy I, Murphy D, Pritchard E, Evans S, **Millar J**, Chalasani V, Rashid P, Winter M, Vela I, Pryor D, Mark S, Lawrentschuk N (2022) Large variation in conservative management of low-risk prostate cancer in Australia and New Zealand. *BJU Int.* Jun;130 Suppl 1(Suppl 1):17-19. doi: 10.1111/bju.15698. Epub 2022 Feb 21. <https://pubmed.ncbi.nlm.nih.gov/35076135/>
67. Panjari M, Robinson PJ, Davis SR, **Schwarz M**, Bell RJ (2014) A comparison of the characteristics, treatment, and outcome after 5 years, of Australian women aged 70+ with those aged <70 years at the time of diagnosis of breast cancer. *J Geriatr Oncol.* Apr;5(2):141-7. doi: 10.1016/j.jgo.2013.12.003. Epub 2014 Jan 5. <https://pubmed.ncbi.nlm.nih.gov/24495702/>
68. Pirie K., Doane M. A., Riedel B., and **Myles P. S.** (2022). Analgesia for major laparoscopic abdominal surgery: a randomised feasibility trial using intrathecal morphine. *Anaesthesia*, 77(4), 428–437. <https://doi.org/10.1111/anae.15651>
69. Rashid I, Sahu G, Tiwari P, Willis C, **Asche CV**, Bagga TK, Ghule P, Bland A. (2024) Malnutrition as a potential predictor of mortality in chronic kidney disease patients on dialysis: A systematic review and meta-analysis. *Clin Nutr.* Jul;43(7):1760-1769. doi: 10.1016/j.clnu.2024.05.037. Epub 2024 Jun 3. <https://pubmed.ncbi.nlm.nih.gov/38852509/>
70. Rhon DI, Kim M, **Asche CV**, Allison SC, Allen CS, Deyle GD. Cost-effectiveness of Physical Therapy vs Intra-articular Glucocorticoid Injection for Knee Osteoarthritis: A Secondary Analysis from a Randomized Clinical Trial. *JAMA Netw Open.* 2022 Jan 4;5(1):e2142709. doi: 10.1001/jamanetworkopen.2021.42709. <https://pubmed.ncbi.nlm.nih.gov/35072722/>
71. **Richardson L**, Lehnbohm E, Baysari MT, Walter S, Day RO, Westbrook JI (2016) A time and motion study of junior doctors' work patterns on the weekend: a potential contributor to the weekend effect? *Intern Med J.* doi:10.1111/imj.13120 <https://pubmed.ncbi.nlm.nih.gov/27094756/>
72. Rieger, E, Costanza, R, Kubiszewski, I, **Dugdale P** (2023) "Toward an Integrated Science of Wellbeing" Oxford University Press
73. **Robinson P** (2021) Petrichor revisited. *Aust N Z J Public Health.* Feb;45(1):3. doi: 10.1111/1753-6405.13091. <https://pubmed.ncbi.nlm.nih.gov/33559963/>
74. Rowland A, van Dyk M, **Warncken D**, Mangoni A, Sorich M, Rowland A (2017) Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. *British Journal of Clinical Pharmacology*, doi: 1111/bcp.13478. <https://pubmed.ncbi.nlm.nih.gov/29178272/>
75. Schofield, P., Hyatt, A., White, A., White, F., Frydenberg, M., Chambers, S., Gardiner, R., Murphy, D. G., Cavedon, L., **Millar, J.**, Richards, N., Murphy, B., & Juraskova, I. (2024). Co-designing an online treatment decision aid for men with low-risk prostate cancer: Navigate. *BJU Compass*, 5(1), 121-141. <https://doi.org/10.1002/bco2.279>
76. Seneviratne, U., McLaughlin, K., Reilly, J., Luckhoff, C., **Myles, P.** (2024). Nine recommendations for the emergency department for patients presenting with low back pain based on management and post-discharge outcomes in an Australian, tertiary emergency department. *EMA - Emergency Medicine Australasia*, 36(2), 310-317. <https://doi.org/10.1111/1742-6723.14354>
77. Song, K., Amatya, B., Meng Zhe, Y., Malik, S., & **Khan, F.** (2025). Clinical practice guidelines for rehabilitation in colorectal cancers: a critical appraisal. *Journal of the International Society of Physical and Rehabilitation Medicine.* <https://doi.org/10.1097/ph9.0000000000000066>

78. Talic S, Shah S, Wild H, Gasevic D, Maharaj A, Ademi Z, Li X, Xu W, Mesa-Eguiagaray I, Rostron J, Theodoratou E, Zhang X, Motee A, **Liew D**, Ilic D (2021) Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis. *BMJ*. Nov 17;375:e068302. doi: 10.1136/bmj-2021-068302. Erratum in: *BMJ*. 2021 Dec 3;375:n2997. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423125>
79. Thien, F., Davies, J. M., **Douglass, J. A.**, & Hew, M. (2025). Thunderstorm Asthma: Current Perspectives and Emerging Trends. *J Allergy Clin Immunol Pract*. <https://doi.org/10.1016/j.jaip.2025.04.001>
80. Tamirat, K. S., Leach, M. J., Papa, N. P., **Millar, J. L.**, & Ristevski, E. (2025). Individuals from culturally and linguistically diverse backgrounds have more advanced prostate cancer at diagnosis in Victoria, Australia. *Cancer Epidemiology*, 97, Article 102827. <https://doi.org/10.1016/j.canep.2025.102827>
81. Tamirat, K. S., Leach, M. J., Papa, N., **Millar, J.**, & Ristevski, E. (Accepted/In press). Patterns of Care and Treatment Outcomes Among Men Diagnosed with Prostate Cancer from Culturally and Linguistically Diverse Backgrounds: A Scoping Review. *Current Oncology Reports*. <https://doi.org/10.1007/s11912-025-01660-8>
82. Whittal A, Nicod E, **Drummond M**, Facey K (2021) Examining the impact of different country processes for appraising rare disease treatments: a case study analysis. *Int J Technol Assess Health Care*. May 28;37(1):e65.doi:10.1017/S0266462321000337. <https://pubmed.ncbi.nlm.nih.gov/34044899/>
83. Wilkie J, Carville, K. Fu, S. **Kerr, R.** et al. (2023) Determining the actual cost of wound care in Australia. *Wound Practice and Research* 2023; 31(1):7-18 <https://doi.org/10.33235/wpr.31.1.7-18>
84. **Wilson J**, You X, Ellis M et al. (2021) VO2max as an exercise tolerance endpoint in people with cystic fibrosis: Lessons from a lumacaftor-ivacaftor trial, *Journal of Cystic Fibrosis* 20(3):499-505. doi: 10.1016/j.jcf.2020.12.006 <https://pubmed.ncbi.nlm.nih.gov/33358691/>
85. Yadav J, Menon GR, Mitra M, Allarakha S, **John D.** (2022) Burden and cost of communicable, maternal, perinatal and nutrition deficiency diseases in India. *J Public Health (Oxf)*. Jun 27;44(2):217-227.doi:10.1093/pubmed/fdaa173. <https://pubmed.ncbi.nlm.nih.gov/32970145/>
86. Yang, M., Amatya, B., Malik, S., Song, K., Marcella, S., Voutier, C., & **Khan, F.** (2025). Effectiveness of rehabilitation interventions in patients with colorectal cancer: an overview of systematic reviews. *J Rehabil Med*, 57. <https://doi.org/10.2340/jrm.v57.40021>
87. Yuan F, Ni H, **Asche CV**, Kim M, Walayat S, Ren J (2017) Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. *Curr Med Res Opin*. Jul;33(7):1191-1197. doi: 10.1080/03007995.2017.1292230. Epub 2017 Mar 7 <https://pubmed.ncbi.nlm.nih.gov/28166427/>
88. Zheng J, Sampurno F, George DJ, Morgans AK, Nguyen H, Abrahm JL, Bjartell A, Davis ID, Fitch MI, Gillessen S, Kanesvaran R, Matthew A, **Millar JL**, O'Sullivan JM, Payne H, Pouliot F, Yates P, Evans SM.(2022) Establishing metastatic prostate cancer quality indicators using a modified Delphi approach. *Clin Genitourin Cancer*. Apr;20(2):e151-e157. doi: 10.1016/j.clgc.2021.11.018. Epub 2022 Jan 7 <https://pubmed.ncbi.nlm.nih.gov/35135748/>
89. Zhou, X. Wu, T, Sang M , Qiu, S, Wang, B, Guo, H., Li, K, Wang, Q, Wang, X Chen, Q, Li, H, S Yan S., Horowitz, M, Rayner, C, Wang, D, **Liew, D** et al (2025) Variations in blood pressure after a 75 g oral glucose load and their implications for detecting hypertension and postprandial hypotension in Chinese adults: a cross-sectional study, *European Journal of Preventive Cardiology*, <https://doi.org/10.1093/eurjpc/zwaf217>



## SECTION 3

## OUR FINANCES

## SIMPLIFIED OPERATING STATEMENT

	2022-2023	2023-2024	2024-2025
<b>Revenue</b>			
<b>Donations</b>	\$1195.73	\$1,202.27	\$1,368.06
<b>Expenses</b>			
<b>Insurance for GENI</b>	\$783.66	\$783.86	\$878.75
Voluntary Workers Personal Accident and Association Liability (Professional and Management Liability etc)			
<b>GENI website (Just Host)</b>			
Plus, Hosting, Site Lock Security	\$286.87	\$293.92	\$354.81
GENI Domain Name Registration	\$25.20	\$24.49	\$34.50
<b>Performance Award Program</b>			
GENI Award for Outstanding Contribution	\$100.00	\$100.00	\$100.00
<b>Total expenditure</b>	\$1,195.73	\$1,202.27	\$1,368.06
<b>Total revenue (donations)</b>	\$1,195.73	\$1,202.27	\$1,368.06



## ACKNOWLEDGMENTS & THANK YOU

### Donor

Dr Kathryn Antioch, Chief Executive Officer, GENI

### Important Key organisations

AHES (Australian Health Economics Society)  
Cochrane Collaboration  
GIN (Guidelines International Network)  
IHEA (International Health Economics Association)  
ISPOR (International Society for Pharmacoeconomics and Outcomes Research)  
National Guideline Clearinghouse AHRQ – Agency for Healthcare Research and Quality, US Department of Health, and Human Services  
NICE (National Institute for Health and Care Excellence)  
NHMRC (National Health and Medical Research Council – Australian Government)  
NHMRC Clinical Practice Guidelines Portal  
NHS Centre for Reviews and Dissemination (including the Economic and Evaluation Database – NHS EED)  
NHS Evidence  
University of Utah, USA  
WHO Health Evidence Network



## CONTACT US

<http://geni-econ.org/contact-us>

